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ABSTRACT 
 
 
 
THE BRAZILIAN-PORTUGUESE MCMI-III: 
DIAGNOSTIC VALIDITY OF THE ALCOHOL DEPENDENCE AND  
DRUG DEPENDENCE SCALES 
 
by 
  
Cristina Lílian Magalhães 
 
Nova Southeastern University 
 
 
 
The Brazilian-Portuguese Millon Clinical Multiaxial Inventory-III (BP-MCMI-
III) is a newly developed translation of the original MCMI-III and requires validation 
before it can be used in cross-cultural research and clinical settings. This study was the 
first validation study with the BP-MCMI-III and examined the validity of its Alcohol 
Dependence and Drug Dependence scales for identifying substance-related disorders in a 
Brazilian sample.  
The diagnostic validity of these scales was examined by comparing participants’ 
scores on the BP-MCMI-III against group status (controls versus patients receiving 
substance abuse treatment) and against clinical diagnoses made based on a DSM-IV-TR 
symptom checklist. In addition, diagnostic validity statistics were also computed for both 
scales. The construct validity of the Alcohol Dependence scale was examined by 
comparing the subjects’ scores with their performance on a Brazilian version of the 
Alcohol Use Disorders Identification Test (AUDIT).  
The total sample used in this study consisted of 126 Brazilians residing in the 
metropolitan area of Rio de Janeiro, Brazil. Of the total sample, 75 were inpatients at 
treatment facilities for substance abuse and 51 were not receiving treatment for alcohol- 
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or drug-related problems at the time of testing. The results of this study supported the 
validity of the BP-MCMI-III for diagnosing substance-related disorders among 
Brazilians.  
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CHAPTER I 
Statement of the Problem 
A Brazilian-Portuguese version of the Millon Clinical Multiaxial Inventory-III 
(BP-MCMI-III) was developed to be used in future studies that will examine cross-
cultural aspects of personality and psychopathology in Brazil and the United States. The 
initial phases of this project were conducted by this researcher and her associates, and 
involved the completion of four preliminary steps in cross-cultural test adaptation: (1) the 
translation phase, which included a series of procedures used to maximize translation 
accuracy and readability; (2) a pilot test-retest study, which evaluated item equivalency 
using a bilingual sample; (3) the revision phase, which involved further refinement of 
problem-items; and (4) a preliminary reliability study, which evaluated the psychometric 
properties of the new version with data collected in Brazil. The results of these studies 
were encouraging and suggested that the translated instrument is psychometrically 
reliable and comparable to the original MCMI-III. Stability coefficients for all scales 
were above .6 and significant at .001 level with the Brazilian sample. The methodological 
procedures for the translation, as well as the results of the bilingual test-retest and the 
preliminary reliability study, were summarized in two unpublished manuscripts 
(Magalhaes, Magalhaes, Sellers & Lewis, 1999; Magalhaes, Magalhaes, Sellers, Lewis, 
Cruz, & Corga, 2004). See Appendices A and B. 
Although test translations used in research and clinical practice are often developed 
in casual and unsystematic ways, the literature offers several guidelines for developing 
quality translations; that is, translations that retain comparable item content and 
psychometric properties with the original instrument and assess the constructs of interest 
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with the same or similar degree of accuracy (Bracken & Barona, 1991; Geisinger, 1994; 
Butcher, 1996a; Butcher, 1996b; Butcher & Hans, 1996; Sperber, Devellis, & Boehlecke, 
1994; Van de Vijver, F., & Hambleton, R. K., 1996). Suggested procedures include not 
only a multistep translation process, like the one described above for the BP-MCMI-III, but 
also a series of validation studies that can offer support for the usefulness of the translated 
instrument for assessing constructs of interest in the target population. The argument is that 
even if the test itself remains unchanged after being translated (linguistically and 
psychometrically speaking), there is no guarantee that it assesses the same construct in a 
different culture or that the new version continues to provide scores that can be interpreted 
in the same manner it was proposed for the original version. 
To date no validation studies have been conducted to evaluate the usefulness of the 
BP-MCMI-III for assessing psychopathology in the Brazilian population. The BP-MCMI-
III, like the original MCMI-III, has a total of 27 subscales: (a) 3 for estimating the 
individual’s test-taking attitude, (b) 14 for measuring different personality styles, and (c) 10 
for assessing the presence of clinical syndromes (Millon, 1997). Because the BP-MCMI-III 
is expected to measure several constructs at the same time, its validation is clearly a 
complex task and requires a systematic approach. 
The validity studies reported in the MCMI-III manual involved the participation of 
several clinicians who administered the test on their own clients. These clinicians then rated 
the presence or absence of various personality traits and symptoms of clinical syndromes for 
each client based on their knowledge of Millon’s theory of personality and psychopathology 
and the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders criteria 
(DSM-IV; American Psychiatric Association, 1994). Familiarity with Millon’s theory 
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was considered to be an important characteristic of the raters because some personality 
patterns assessed by the instrument can not be easily identified using the DSM-IV criteria 
only. The following is a section included in the Rating Reference Booklet provided to 
participating clinicians: 
“Our view here is that personality is not expressed only in the cognitive, 
or behavioral, or psychodynamic, or interpersonal realms, but is instead 
manifested across all of these clinical domains, and that the DSM is 
markedly incomplete with regard to its sampling of many domains of 
clinical expression. You should attempt to use both DSM and Millon 
criteria when making your personality rating decisions.” (Millon, 1997, p. 
90). 
Since the use of raters trained on Millon’s theoretical approach was not feasible at 
this time, this investigator selected two clinical syndrome scales – the Alcohol Dependence 
and Drug Dependence scales – to be the focus of this study. Unlike the personality scales, 
the MCMI-III clinical syndrome scales were expected to correspond more directly to the 
current diagnostic nomenclature with which most clinicians and researchers are familiar – 
the DSM-IV-TR. Diagnosis made based on DSM-IV-TR criteria could then serve as a “gold 
standard” to which diagnosis made based on the MCMI-III could be compared. 
The decision to select the substance dependence scales for this study, among other 
clinical syndrome scales, was based primarily on this investigator’s clinical interest in the 
field of substance abuse and on the relative ease of gathering clinical data on this clinical 
population. Although several instruments for assessing alcohol and drug use are available, 
the MCMI-III is unique in that it provides the opportunity for assessing addictive behaviors 
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in the context of personality styles and general psychopathology. The results of this study 
will provide relevant information regarding the validity of the BP-MCMI-III for assessing 
substance use problems in the Brazilian population. 
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CHAPTER II 
Review of the Literature 
Principles of Test Validation 
The validity of a test is defined simply as an estimate of how well the test 
measures what it is supposed to measure. Thus, procedures for determining validity 
typically involve ways of understanding the relationship between a subject’s performance 
on the test and his performance on some other measure or measures of the same 
characteristic (the criterion) being studied.  
The literature describes several types of validity and several methods for 
estimating validity. A common procedure, content validation, involves evaluating the 
extent a test measures a representative sample of all characteristics of the domain being 
assessed. Although content validity is expected to be built into a test from its 
development (through the choice of appropriate items), it can never be assumed. Potential 
threats to content validity include the following: (a) test items may not cover all major 
aspects of the domain being assessed, (b) test items may cover all aspects but not in the 
correct proportions, or (c) some items may be irrelevant. Procedures to ensure content 
validity are usually fairly simple. They involve consultations with experts who provide 
information on the importance of specific characteristics that need to be assessed with the 
test and a systematic examination of the test items to see if they cover all relevant aspects 
identified by the experts (Anastasi & Urbina, 1997).  
Content validity is considered to be of major importance for evaluating the 
usefulness of tests that measure a person’s skill or knowledge of a certain topic, such as 
with achievement tests. However, Anastasi and Urbina (1997) stated that content 
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validation alone is usually inappropriate, or even misleading, for personality tests due to 
the fact that these tests may not necessarily bear any resemblance to the behavior domain 
they hope to sample. Because personality tests are typically developed based on a 
researcher’s theory, it may be impossible, just by looking at the content of the items, to 
determine what is really being measured. Thus, in the case of personality inventories such 
as the BP-MCMI-III, construct-identification procedures are considered to be of greater 
relevance. 
Construct validity refers to the extent a test appropriately measures a construct or 
a trait that is theoretically defined and typically involves the gradual accumulation of 
evidence from a variety of sources. Because any given psychological construct can be 
operationalized in various ways, different gauges (single test items) can be created, each 
assessing different aspects of the construct and none fully capturing the almost infinite 
number of descriptive variables associated with that construct. For example, alcohol 
dependence can be measured directly or indirectly (depending on how it is theoretically 
defined) by assessing frequency of drinking days, amount of alcohol consumed on a 
typical drinking day, frequency and severity of relationship problems caused by drinking, 
amount of time spent drinking, frequency of impulsive behavior in various situations, 
ability to effectively cope with stressful situations, or level of occupational functioning, 
just to name a few associated variables. Given that psychological constructs are complex 
theoretical entities, it is reasonable then to expect that any single study aiming at 
establishing construct validity of an instrument must fail to fully capture its multifaceted 
nature (Davis, Wenger & Guzman, 1997). Correlations with other tests (criterion 
measures), factor analysis, internal consistency, convergent and discriminant validation, 
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and structural equation modeling procedures are some of the methods usually employed 
to evaluate construct validity (Anastasi & Urbina, 1997; Millon, 1997).  
Another type of validity, criterion-predictive validity, refers to how well a 
subject’s performance on a test predicts his performance in the future in some other 
measure. Although this method is especially appropriate for tests used in the selection of 
individuals for jobs or educational programs (e.g., predicting how well a person would 
perform certain tasks at a new job), it may also be used to predict clinical outcome; for 
example, to evaluate an individual’s probability of benefiting from one form of treatment 
versus another. A broader definition of criterion-predictive validity can also include 
evaluating how well a test can predict a person’s performance on another measure that is 
administered concurrently or predict the person’s inclusion on a particular category (e.g., 
a diagnosis), in which case the time factor (predicting into the future) would not be 
relevant (Anastasi & Urbina, 1997).  
Diagnostic Validity Indices 
A special form of predictive validity, diagnostic validity, is considered to be an 
important characteristic of a diagnostic tool such as the MCMI and will be the primary 
focus of this proposed study. The diagnostic validity or efficiency of a test is typically 
measured in terms of the test’s operating characteristics, which include prevalence, 
sensitivity, specificity, positive predictive power, negative predictive power, and overall 
diagnostic power (Retzlaff, 1996; Retzlaff & Gibertini, 1994).   
Prevalence is estimated based on a particular sample composition and is 
calculated by dividing all disordered cases (true and false positives) by the number of 
subjects in the sample. For practical purposes, prevalence refers to the probability that a 
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particular person has the disorder the test measures before any further information is 
known.  
Sensitivity refers to how well a diagnostic instrument detects a particular disorder 
or a cluster of symptoms; in other words, how sensitive a test is in the presence of the 
disorder. Sensitivity is calculated by dividing the number of cases identified by the test as 
having a disorder (test positives) by the total number of cases having the disorder 
(including true positive cases not identified by the test). Although considered a very 
important operating characteristic, sensitivity alone tells us very little about the validity 
of a diagnostic instrument. For example, a test can be highly sensitive (able to identify 
100 percent of true positive cases in a particular sample) and, at the same time, 
misdiagnose several cases, finding pathology when it does not exist (false positives).  
Specificity, on the other hand, refers to the degree to which a test detects a specific 
disorder and excludes other pathologies; that is, whether the test is specific enough to 
identify as positive those cases that truly have the disorder. Specificity is calculated by 
dividing the number of cases not identified by the test as having the disorder (including 
true and false positives) by the total number of true negative cases. Thus, if we frame the 
operating characteristics of a test in terms of conditional probabilities, specificity can be 
defined as the probability that the test is negative given the disorder is absent, whereas 
sensitivity would be the probability that the test is positive given the disorder is present 
(Gilbertini, Brandenburg, & Retzlaff, 1986). 
Specificity and sensitivity are usually considered to be independent of the 
prevalence of the disorder in the sample; in other words, a test should identify the same 
proportion of disordered cases across samples. However, calculating these two indices 
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requires that one knows which cases in the sample really have the disorder the instrument 
is supposed to detect. Therefore, sensitivities and specificities are dependent on the 
accurate classification of subjects into appropriate diagnostic categories. 
Positive predictive power (PPP) is defined as the proportion of positive cases that 
actually have a disorder and it is equal to the number of true positives divided by the 
number of test positives. Negative predictive power (NPP) is the proportion of 
individuals identified as negative cases that in fact do not have the disorder. This index is 
calculated by dividing true negatives by test negatives. Both predictive power indices are 
influenced by the prevalence of the disorder in the population and the magnitude of the 
sensitivity and specificity of the test. Generally speaking, these indices are optimal when 
sensitivity and specificity are above 90%. However, even a very good test (a test with 
high sensitivity and high specificity) loses positive predictive power when prevalence 
falls below 10% (Gilbertini, Brandenburg, & Retzlaff, 1986).  In addition, in the absence 
of good specificity, positive predictive power and sensitivity tend to be inversely related. 
That is, when the sensitivity of an instrument increases, false positives increase, and 
positive predictive power declines (Millon, 1997).  
Compared to specificity and sensitivity, predictive power indices are considered 
more useful to the practitioner making decisions about individual patients but are often 
not reported in test manuals because the data necessary to determine them is rarely 
collected. According to Gilbertini, Brandenburg, and Retzlaff (1986), “the following are 
needed: (a) an empirically based estimate of the prevalence of the disorder in the 
population on which the test will be used, (b) the valid assignment of patients to 
diagnostic categories, and (c) an independent administration of the test to the selected 
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sample.” The assignment of sample patients to groups (criterion b) can also serve as the 
estimation procedure for population prevalence (criterion a), but the administration of the 
test under consideration must be conducted independently from the assignment process 
(criterion c). 
Lastly, overall diagnostic power (DxP) is a global index of a test’s overall 
classification accuracy. Generally speaking, this index is a combination of the two 
predictive power indices and reflects the proportion of correctly classified subjects 
according to the presence or absence of a disorder. Although often reported in test 
manuals, high overall diagnostic power can be very misleading because it is possible to 
have a high overall diagnostic power even when the number of false positives and false 
negatives are greater than the number of true positives, especially when the prevalence of 
the disorder is low (Gilbertini, Brandenburg, and Retzlaff, 1986).  
Although used less frequently in the MCMI literature, five additional measures of 
diagnostic validity should also be discussed in this section. These are the Incremental 
Validity of Positive Test Diagnoses, the Incremental validity of Negative Test Diagnoses 
(INPP), Cohen’s Kappa, Cohen’s Effect Size, and Area Under ROC Curves.  
The Incremental Validity of Positive Test Diagnoses (IPPP) is the difference 
between a scale’s positive predictive power and the prevalence of the disorder in the 
sample. Even though some experts in the field have emphasized the importance of 
positive predictive power over other validity measures (Retzlaff, 1996; Millon, 1997), 
Hsu (2002) pointed out that this diagnostic index has some limitations and should be 
interpreted with caution. His argument is that in the absence of any correlation between 
test scores and a disorder, positive predictive power is expected to be equal to prevalence 
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(Gibertini et al., 1986; Kraemer, Kazdin, Offord, Kessler, Jensen, & Kupfer, 1999; both 
cited in Hsu, 2002). Thus, one can say that diagnoses made by the test are preferable to 
diagnoses assigned randomly only when positive predictive power is greater than 
prevalence. IPPP then provides a measure of how much better than chance a test makes a 
diagnosis. IPPP values range from zero to plus or minus 1.0, with zero indicating that 
test-based positive diagnoses are equal to chance and the maximum value of 1.0 
indicating that the test produces no diagnostic errors. Negative values indicate that test-
based classifications are worse than chance.  
Similarly to IPPP, the Incremental Validity of Negative Test Diagnoses (INPP) 
provides a measure of how much better than chance a test correctly identifies cases 
without the disorder; and it is defined as the difference between a scale’s negative 
predictive power and the prevalence rate of patients not having the disorder. INPP values 
also range from zero to plus or minus 1.0, with zero indicating that test-based negative 
diagnoses are equal to chance and 1.0 indicating that the test is 100 percent valid in 
detecting no pathology. Negative values indicate that test-based classifications are worse 
than chance (Retzlaff, 2000; Hsu, 2002).  
Although best known as a measure of interrater agreement, Cohen’s Kappa can 
also be used as a measure of the combined incremental validities of positive and negative 
test diagnoses (IPPP and INPP) relative to random assignment of diagnoses. That is, it 
can compare the proportion of correct positive and negative test-based diagnoses to the 
proportion of correct positive and negative diagnoses made by chance. Similarly to IPPP 
and INPP, maximum value of Cohen’s Kappa is 1.0. Negative values indicate that test-
based diagnoses are worse than chance, zero indicates it is equal to chance, and 1.0 
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indicates that diagnoses (positive and negative) are 100 percent accurate (Hsu, 2002; 
Huck, 2000).  
It should be noted that Cohen’s Kappa, predictive power indices (PPP and NPP), 
and incremental validities of positive and negative test diagnoses (IPPP and INPP) are 
affected by prevalence and base rates. Thus, values for these diagnostic validity measures 
tend to vary greatly depending on the characteristics of the sample used to derive data. 
Cohen’s Effect Size (d) is independent from prevalence and base rates, and can serve as a 
measure of the relative ability of a test to discriminate between groups.  
Lastly, the Area Under ROC (receiver operating characteristic) Curves, also 
known as AUC, has been recently recognized in the literature as another measure of 
diagnostic validity that is free from the effects of prevalence and cut-scores. ROC 
analysis is part of a field called "Signal Detection Theory" and was originally developed 
during World War II for the analysis of radar images (Tape, 2004).  Advantages of AUC 
are its simplicity and generalizability (McGraw & Wong, 1992; cited in Hsu, 2002). Both 
Cohen’s (d) and AUC are considered robust to moderate violations of the normality and 
homogeneity of variance assumptions (Hanley, 1988; McFall & Treat, 1999; McGraw & 
Wong, 1992; cited in Hsu, 2002). 
Validation of the MCMI Substance Dependence Scales 
This section will review the methodological procedures and research findings that 
support the validity of the substance dependence scales for the three generations of the 
MCMI. The reason for discussing the three MCMI versions, rather than simply focusing 
on the latest, is that, according to Millon (1997), validity of each newer version is largely 
supported by the validity of the previous.  
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Content Validity 
According to Millon (1997), validation of the MCMIs was accomplished in three 
stages. The first stage, theoretical-substantive, addressed content validity, by examining 
the extent the items that make up the various scales derived their content from Millon’s 
theory of personality and his definitions of clinical syndromes (Millon, 1981). The 
Alcohol Dependence scale was designed to detect individuals who have a history of 
alcoholism, had tried to overcome the problem with minimal success, and are 
experiencing difficulties in the family and work setting as a result of drinking. Similarly, 
the Drug Dependence scale was designed to detect individuals with recurrent or recent 
histories of drug abuse, who are finding it difficult to restrain their impulses to use/abuse 
drugs, and are unable to manage the consequences of their behavior. Many subtle and 
indirect items were included in both scales in an attempt to identify individuals who were 
not ready to admit their substance use problems. Millon’s rationale for including these 
scales in the MCMI was to provide the opportunity for studying an individual’s substance 
use problems in the context of his overall personality style (Millon, 1997). 
Reliability 
The second validation stage, internal-structural, first examined the internal 
consistency of the various scales and selected the items that maximized scale 
homogeneity. Each scale was expected to have a high degree of internal consistency, 
display a considerable overlap with some of the other scales, and demonstrate satisfactory 
levels of endorsement frequency and reliability over time. In the case of the MCMI-III, a 
research form was initially developed, consisting of the 175 items from the MCMI-II and 
150 new items, which together made up a larger item pool from which item selection for 
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the MCMI-III was made. Endorsement rates for each of the 325 items were examined to 
ensure that it fell within an acceptable range, and items with very high or very low 
endorsement frequencies were eliminated. Several statistics were then computed and 
recomputed simultaneously as items were added or removed from their respective scales. 
This process allowed for the identification of the best item composition for each scale 
based on statistical and substantive criteria. Chronbach’s alphas (N = 398) and test-retest 
correlation coefficients (N = 87) were calculated for the resulting scales, which now 
comprise the MCMI-III. The Chronbach’s alphas obtained for the Alcohol and Drug 
Dependence scales were .82 and .83, respectively. Test-retest reliability coefficients for 
these scales were .92 and .91. Table 1 presents the results for all scales. 
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Table 1 
Length, Internal Consistency, and Test-Retest Reliability of the MCMI-III Scales 
  Number 
of Items 
 Internal 
Consistencya
 Test-Retest 
Reliabilityb
Clinical Personality Patterns      
1 Schizoid 16  .81  .89 
2A Avoidant 16  .89  .89 
2B Depressive 15  .89  .93 
3 Dependent 16  .85  .89 
4 Histrionic 17  .81  .91 
5 Narcissistic 24  .67  .89 
6A Antisocial 17  .77  .93 
6B Sadistic (Aggressive) 20  .79  .88 
7 Compulsive 17  .66  .92 
8A Negativistic 16  .83  .89 
8B Masochistic 15  .87  .91 
Severe Personality Pathology      
S Schizotypal 16  .85  .87 
C Borderline 16  .85  .93 
P Paranoid 17  .84  .85 
Clinical Syndromes      
A Anxiety 14  .86  .84 
H Somatoform 12  .86  .96 
N Bipolar: Manic 13  .71  .93 
D Dysthymia 14  .88  .91 
B Alcohol Dependence 15  .82  .92 
T Drug Dependence 14  .83  .91 
R Post-Traumatic Stress Disorder 16  .89  .94 
Severe Clinical Syndromes      
SS Thought Disorder 17  .87  .92 
CC Major Depression 17  .90  .95 
PP Delusional Disorder 13  .79  .86 
Modifying Indices      
X Disclosure NA  NA  .94 
Y Desirability 21  .86  .92 
Z Debasement 33  .95  .82 
aCross-Validation Sample (N = 398) 
bTest-Restest Interval = 5-14 days (N = 87) 
 
Base Rate Development 
Unlike most tests, the MCMI uses Base Rate (BR) scores, instead of T scores, to 
transform raw data into interpretable information. Created through criterion referencing 
(not norm referencing), BR scores are anchored to the prevalence rate of personality 
characteristics and clinical syndromes in the psychiatric population. Consistent with 
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Millon’s theory of personality, the MCMI assumes that the difference between a clinical 
disorder and normal functioning is a matter of degree rather than kind; that is, traits and 
symptoms are viewed in a continuum (Millon, 1981; Millon, 1997).  
Base Rate development was completed also during the internal-structural stage of 
the test’s validation process. First, the target prevalence of each of the characteristics 
represented by 24 clinical scales were established “by calculating the proportion of times 
clinicians rated each trait as a client’s most prominent problem (the prominent prevalence 
rate) or as present but not as prominent as the first (the present prevalence rate)” (Millon, 
1997; pg. 60).  For the 11 scales measuring clinical personality patterns, two additional 
prevalence rates were calculated: the trait prevalence rate, indicating the proportion of 
time clinicians rated each personality pattern as a trait; and the disorder prevalence rate, 
indicating the proportion of time personality patterns were rated as disorders. These 
prevalence rates were then adjusted based on results of various epidemiological studies to 
develop the final criteria used to create the BR scores. The anchoring of BR scores was 
accomplished by determining the equivalence of a BR score of 0 to a raw score of 0, a 
BR of 60 to the median raw score, and a BR of 115 to the maximum attained raw score. 
Cut-off scores were determined as follows: scores of 75 and above indicate the presence 
of a trait or clinical syndrome; while scores of 85 and above indicate the presence of a 
disorder or prominence of a syndrome. Table 2 shows BR transformations for the 
Alcohol Dependence (B) and Drug Dependence (T) Scales.  
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Table 2 
BR Transformations for the Alcohol Dependence (B) and Drug Dependence (T) Scalesa 
 BR Scale Scores 
Raw Males Females 
Score B T B T 
0 0 0 0 0 
1 15 15 25 25 
2 30 30 60 60 
3 45 45 61 62 
4 60 60 62 63 
5 65 62 63 64 
6 70 63 64 65 
7 75 65 68 66 
8 77 67 70 67 
9 79 68 71 68 
10 81 70 75 70 
11 83 72 78 75 
12 85 73 80 80 
13 88 75 82 85 
14 92 78 85 91 
15 95 82 90 97 
16 98 85 95 103 
17 102 92 100 109 
18 105 98 105 115 
19 108 104 110 115 
20 112 110 115 115 
21 115  115  
aMillon (1997). 
 
Diagnostic Validity of the original MCMI 
Evidence of the MCMI value as a diagnostic tool was gathered in the third and 
final validation stage – the external-criterion stage. The diagnostic validity of the first 
MCMI was estimated based on a study with 978 psychiatric patients with mixed 
diagnoses. According to Millon (1983), the results of this study indicated that the Alcohol 
Abuse and Drug Abuse scales were effective in detecting individuals with substance 
abuse histories. McMahon, Flynn, and Davidson (1985), in a study involving repeated 
administrations of the MCMI throughout treatment, found that scores on the substance 
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abuse scales in fact remained significantly elevated over time (whereas other scales were 
less stable), indicating that the MCMI was able to detect the subjects’ substance abuse 
histories independent of current use.  
While the Alcohol Abuse and Drug Abuse scales were found to be generally 
elevated among substance abuse patients in some studies (Flynn & McMahon, 1984; 
Stark & Campbell, 1988; McMahon, Flynn, and Davidson, 1985), other investigators 
questioned the MCMI substance abuse scales’ diagnostic value and raised concern about 
the content of the scale items and the independence of these scales. In a study with 561 
psychiatric inpatients, using the standard base-rate cutoff score of 75, Bryer, Martines, 
Dignan (1990) found that subjects who scored positive for substance abuse by the test, 
more often than not, did not have the substance-abuse history that the particular scale had 
predicted. They explained their findings by calling attention to the fact that the MCMI 
Alcohol Abuse scale had only 7 out of 31 questions with specific alcohol abuse content 
and the Drug Abuse scale had 5 out of 46 items with drug content. 
In a study with opiate-addicts, Marsh, Stile, Stoughton, and Trout-Landen (1988) 
found that only 49% of clinical cases in their sample had significant elevations on the 
Drug Abuse scale. With college students, Jaffe and Archer (1987) found that MCMI 
Alcohol Abuse scale was more effective in detecting drug abuse than was the Drug 
Abuse scale. They explained their findings by pointing out a large intercorrelation 
between the two scales (r = .65), a very different number than the one originally reported 
by Millon (r = -.08; Millon, 1983).  
Wetzler (1990) wrote an article reviewing all major studies with the first MCMI 
and offered a possible explanation for the poor diagnostic efficiency that was implied by 
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these studies. He noted that studies that used structured-interview based criterion 
diagnoses generally found adequate diagnostic efficiency for the MCMI, while those that 
used diagnoses given by psychiatrists during their standard clinical evaluations found 
poor diagnostic efficiency. His conclusion was that, despite its shortcomings, the MCMI 
was probably a better diagnostician that the average clinician.  
With regards to the instrument’s operating characteristics, the first MCMI manual 
reported only sensitivity and specificity values (Millon, 1977). The full set of operating 
characteristics of the scales were later calculated and reported by Gilbertini, 
Brandenburg, and Retzlaff (1996). The overall diagnostic power (DxP), specificities 
(Spec) and negative predictive powers (NPP) were found to be generally high; while 
sensitivities (Sens) and positive predictive powers (PPP) varied greatly (sensitivities 
ranged from 15% to 91% and PPPs from 19% to 84%). See Tables 3 and 4 for values 
concerning the alcohol Abuse and Drug Abuse scales. 
Table 3 
Operating Characteristics of the MCMI Substance Abuse Scales (BR > 74) 
Scale Prevalence Sensitivity Specificity PPP NPP DxP 
Alcohol Abuse 17 74 91 63 95 88 
Drug Abuse 11 78 96 71 97 94 
 
Table 4 
Operating Characteristics of the MCMI Substance Abuse Scales (BR > 84) 
Scale Prevalence Sensitivity Specificity PPP NPP DxP 
Alcohol Abuse 12 56 96 66 94 91 
Drug Abuse 6 52 98 63 97 95 
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Diagnostic Validity of the MCMI-II 
Released in 1987, the MCMI-II retained most of the items that were part of the 
original MCMI scales, although both substance abuse scales contained new items. 
Similarly to the MCMI, the MCMI-II substance abuse scales had few items with obvious 
drug and alcohol content (Bryer et al., 1990). The two scales had 25 items in common 
and were reported to have an intercorrelation of .76 (Millon, 1987). Millon’s response to 
those who criticize the MCMI for its high scale intercorrelations has always been one; 
that the scales overlap is consistent with his theory and that it was intentionally built into 
the test to account for the complex nature of the constructs being measured (Millon & 
Millon, 1997; Wetzler, 1990). For example, the two substance dependence scales are 
expected to measure different but similar constructs, since individuals with alcohol and 
drug problems are likely to have tried to overcome their substance abuse problem with 
minimal success and experience difficulties in the family and work setting as a result of 
the addiction.  
Despite the MCMI and MCMI-II recognized overall diagnostic validity 
(Gibertini, 1993), Fals-Stewart (1995) alerted clinicians to the effect of defensive 
responding (i.e., fake-good) on the instrument’s substance abuse scales. He compared the 
scores of substance abuse patients who were asked to respond honestly with those asked 
to respond defensively and also with forensic subjects suspected of abusing psychoactive 
substances. The results indicated that, even though most MCMI-II items comprising the 
substance abuse scales do not directly concern alcohol and drug use, most people 
motivated to deny substance abuse can avoid detection. He concluded then that, in 
 
 
 23
situations when individuals may feel compelled to hide substance abuse symptoms, 
validity of the MCMI-II substance abuse scales may be threatened. 
Three studies provided initial support for the validity of the MCMI-II at the time 
of its release. These studies examined the extent to which scale scores corresponded to 
diagnoses made by clinicians in accordance with the revised 3rd edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-III-R; American Psychiatric 
Association, 1987) criteria. Based on the results of these studies, Millon reported that 
both the Alcohol Dependence and Drug Dependence scales corresponded extremely well 
with a diagnosis of alcohol dependence and drug dependence. Their overall diagnostic 
power was estimated to be 97% and 94%, respectively (Millon, 1997). Patients diagnosed 
with alcohol dependence were reported to also show elevations on Antisocial and 
Aggressive scales in Study 1 (N = 20) and on Schizoid and Drug Dependence scales in 
studies 2 and 3 combined (N = 43). Patients diagnosed with drug dependence also scored 
high on the Alcohol Dependence and Antisocial scales (N = 25 in study 1; N = 53 in 
study 2 and 3 combined). A full set of operating characteristics for all scales was reported 
in the MCMI-II manual, showing higher positive predictive powers (ranging from .30s to 
.80s) than those found with the MCMI (Millon, 1987; cited in Retzlaff, 1996).  
Diagnostic Validity of the MCMI-III 
Even though Millon claims that the studies conducted with the three generations 
of the MCMI can offer support for the validity of its last version (Millon, 1997), there is 
disagreement with regards to what extent the MCMI-III is comparable to the MCMI-II. 
Some researchers believe that the MCMI-III is sufficiently different and should be 
considered a separate instrument (Marlowe, Festinger, & Kirby, 1998; Rogers, Salekin, & 
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Sewell, 1999). In fact, in the case of the substance abuse scales, significant changes were 
made in the number of items. The Alcohol Dependence scale contained 31 items in the 
original MCMI, 46 in the MCMI-II, and only 15 on the MCMI-III. The Drug 
Dependence scale consisted of 46 items in the MCMI, 58 in the MCMI-II, and only 16 on 
the MCMI-III.  
The validity studies reported in the MCMI-III manual used a similar procedure to 
the one used with the MCMI-II; patients’ scale scores were compared with diagnoses 
made by clinicians on the basis of the 4th edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria (Millon, 
1994; cited in Millon 1997). Only prevalences, sensitivities, specificities and test 
positives were initially made available by the test developers. However, using the data 
provided in the test manual, Retzlaff (1996) ran a more complete analysis of the 
operating characteristics of the MCMI-III and found overall lower PPPs than those 
obtained for the MCMI-II, raising a concern that the instrument had lost its diagnostic 
properties. See Table 5.  
 
Table 5 
The 1994 Study: Prevalence, Sensitivity, Specificity, and Predictive Power Values for 
the MCMI-III Substance Abuse Scalesa   
Scale Prevalence Sensitivity Specificity PPP NPP 
Alcohol Abuse 12.40 72.70 85.80 42 96 
Drug Abuse 8.20 51.70 94.80 47 96 
aRetzlaff (1996). 
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Considering that the MCMI-III remained very similar to the MCMI-II in terms of 
its overall scale composition and reliability, Retzlaff (1996) argued that the poor results 
were more likely due to a faulty validity study than to a poorer test. He pointed out 
several methodological problems in the 1994 study, including limitations of the 
diagnostic criteria employed (e.g., clinicians were asked to make diagnoses based on the 
new DSM-IV criteria, which was unavailable at the time), the superficial level and low 
frequency of contact between clinical judges and patients (e.g., clinicians diagnosed cases 
with as low as one clinical contact), and the diversity in purposes of the study (the 
validity study was mixed-in with the item-selection study), among other problems.  
In response to Retzlaff’s article, MCMI developers carried out a new validity 
study with the MCMI-III in an attempt to replicate the conditions under which the 
MCMI-II study was conducted (e.g., in the new study, raters had to have seen the patients 
for at least three therapeutic sessions and had to have a good understanding of the 
patient’s clinical features and personality characteristics before making a diagnosis). The 
revised MCMI-III manual (Millon, 1997) described the methodology used in this study 
and provided a comparative table of diagnostic efficiency statistics across the three 
generations of the MCMI (see Tables 6 and 7 for the Alcohol Dependence and Drug 
Dependence scales statistics). According to the test developers, specificities and NPPs 
were not reported due to the fact that these statistics tend to be grossly inflated for the 
MCMI because of the number of scales included in the calculations (Millon, 1997; Davis, 
Wenger, & Guzman, 1997). Nevertheless, Retzlaff (2000) calculated NPPs with the new 
data and found that they were all equal or greater than .94. Overall, values for the 
diagnostic validity statistics for the second study were found to be much higher than 
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those derived from the first, suggesting that the 1994 study underestimated the diagnostic 
value of the MCMI-III (Millon, 1997; Retzlaff, 2000).  
 
Table 6 
The 1997 Study: Comparative Table of the Operating Characteristics of the Three 
Generations of the MCMI Substance Abuse Scales at BR equal or higher than 75a
 Prevalence Rates  Sensitivity  Positive Predictive 
Power 
 M-I M-II M-IIIb  M-I M-II M-IIIb  M-I M-II M-IIIb
Alcohol 
Abuse 
17 15 30  74 87 86  63 92 83 
Drug     
Abuse 
11 13 19  78 72 92  71 82 89 
aMCMI-III values were calculated from data obtained in the 1997 study (Millon, 1997). 
bStatistic calculated using all disorders judged by clinicians as present. 
 
Table 7 
The 1997 Study: Comparative Table of the Operating Characteristics of the Three 
Generations of the MCMI Substance Abuse Scales at BR equal or higher than 85 a
 Prevalence Rates  Sensitivity  Positive Predictive 
Power 
 M-I M-II M-
IIIb
M-
IIIc
 M-I M-II M-
IIIb
M-
IIIc
 M-I M-II M-
IIIb
M-
IIIc
Alcohol 
Dependence 
12 8 30 17  56 79 65 80  66 88 91 88 
Drug 
Dependence 
6 9 19 11  52 62 78 82  63 78 92 93 
aMCMI-III values were calculated from data obtained in the 1997 study (Millon, 1997). 
bStatistic calculated using all disorders judged by clinicians as present. 
cStatistic calculated using disorders judged by clinicians as most prominent. 
 
After reviewing the methodology and results of these two MCMI-III validity 
studies, Hsu (2002) concluded that the 1994 study, despite its limitations, provided a 
better appraisal of the validity of the MCMI-III. He argued that even though the 1997 
study overcame the major limitation of the 1994 study (lack of familiarity of clinicians 
 
 
 27
with patients), it did not provide adequate control for “criterion contamination, 
confirmatory bias, or availability heuristics;” thus, providing an overestimation of the 
validity of the MCMI-III. According to Hsu (2002), a major methodological flaw of the 
1997 study is that, in order to obtain a large clinical sample, clinicians were encouraged 
to include subjects who had already taken the MCMI-III. Although they were asked not 
to include those patients for whom they had a clear recollection of MCMI-III scores, it is 
hard to believe that prior knowledge of patients profiles did not influence their clinical 
judgment; “after all, it is precisely this type of information that clinicians would be 
expected to pay attention to and remember, especially if they believed that the MCMI-III 
scale elevations yielded useful clinical information” (p. 420).  In addition, clinicians were 
provided with a single rating form to enter both their clinical ratings of the patients’ 
symptoms and traits and the subjects’ MCMI-III scores. Thus, even if clinicians had no 
clear recollection of the patients’ scores at the time of the study, having to enter these 
scores on the same form they recorded diagnoses may have biased their clinical 
judgment.  
In the same article, Hsu (2002) also discussed the importance of diagnostic 
validity indices used less frequently in the MCMI literature that make adjustments for 
chance agreement of scale scores and for inability of a scale to discriminate between 
groups (IPPP, INPP, Cohen’s Kappa, Cohen’s Effect Size, and AUC). He demonstrated 
that, if consideration had been given to these indices, different conclusions about the 
1994 study would have been reached. In spite of the importance researchers traditionally 
place on PPPs, Hsu (2002) argued that low PPPs do not imply worse-than-chance 
diagnoses. In fact, based on the 1994 data, he found that 20 out of the 24 MCMI-III 
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scales performed better-than-chance. With regards to the substance abuse scales, IPPP 
and INPP values were .296 and .084 for Alcohol Dependence; and .388 and .042 for 
Drug Dependence, respectively. Cohen’s Kappa for the Alcohol Dependence scale was 
.454, and .465 for the Drug Dependence scale. Effect sizes were above 1.5 for both 
scales. Diagnostic validity values based on the 1997 study were much higher than values 
based on the 1994 study but should be interpreted with caution due to possible 
overestimation. See Table 8 for values reported by Hsu (2002).  
 
Table 8 
Comparative Table of the 1994 and 1997 Additional Diagnostic Validity Values for the 
MCMI-III Alcohol and Drug Dependence Scalesa  
 PPP IPPP INPP Cohen’s k Cohen’s d AUC 
 1994 1997 1994 1997 1994 1997 1994 1997 1994 1997 1994 1997 
Alcohol 
Dependence 
.420 .88 .296 .71 .084 .13 .454 .81 1.68 2.85 .882 .98 
Drug 
Dependence 
.470 .93 .388 .82 .042 .09 .465 .86 1.67 3.34 .881 .99 
aHsu (2002). 
  
 
Although several independent studies provided additional information on the 
validity of the original MCMI substance abuse scales, only one independent study with 
substance abusers was conducted with the MCMI-III (Craig, 1997). This study reported 
sensitivity and specificity rates for the Alcohol Dependence and Drug Dependence scales 
with a sample of 164 substance misusers from an inpatient drug treatment and 
rehabilitation program. All subjects met diagnostic criteria for opiate or cocaine 
dependence and 80 percent of the sample had a concurrent diagnosis of alcohol abuse or 
alcohol dependence. The results showed an overall sensitivity level of .80 for the Alcohol 
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Dependence scale and .82 for the Drug Dependence scale. Because prevalence of drug 
use was 100 percent, no specificity and NPP values for the Drug Dependence scale were 
obtained with this sample. Specificity for the Alcohol Dependence scale was .59 and NPP 
was .62. PPP values were 1.0 for Drug Dependence and .84 for Alcohol Dependence. 
Because all subjects in this sample were in treatment for substance abuse (prevalence was 
100 percent for drug abuse and 80 percent for alcohol abuse), the high PPP values 
obtained for both substance abuse scales are not surprising.  
Concluding Remarks 
The Millon Clinical Multiaxial Inventory is considered to be one of the major 
personality inventories in the United States, having spawned more than 600 papers since 
its first publication in 1977. Overall, the instrument is considered to be a well-designed 
and psychometrically stable inventory, distinguishing itself from a number of comparable 
tests currently available in the market (Aiken, 1997; Groth-Marnat, 2003). The 
instrument’s success among clinicians and researchers is due to its several distinguishing 
features, including relative brevity (when compared with similar personality inventories 
such as the Minnesota Multiphasic Personality Inventory - MMPI), strong theoretical 
basis, simplicity of administration and scoring, multiaxial format, and consonance with 
the DSM-IV (Choca & Van Denburg, 1997; Craig, 1997, Millon, 1997).  
With regards to its usefulness for detecting substance abuse problems, the MCMI is 
unique in that it provides the opportunity for assessing addictive behaviors in the context of 
personality styles and psychopathology. Millon’s theory predicts that clinical syndromes, 
such as substance abuse or dependence, tend to emerge under periods of greater stress and 
are often reflective of disturbances in underlying personality patterns. A discussion of 
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personality clusters associated with substance abuse is beyond the scope of this proposed 
study. For a review of the literature on this topic, please refer to Choca and Van Denburg, 
1997; and Flynn and McMahon, 1997.  
Cross-Cultural Applications of the MCMI 
The Challenges of Cross-Cultural Assessment 
The field of cross-cultural psychology has grown considerably over the last 
several decades, raising awareness among clinicians and researchers of the need for the 
development of culturally-sensitive assessment practices (Aponte & Crouch, 2000; Dana, 
2000). Recognition of the impact of sociocultural factors in intelligence, personality, 
psychopathology and other constructs of interest to psychologists has led to efforts to 
develop psychological instruments guided by one of two underlying approaches: (a) one 
that seeks to create universal definitions of normality and abnormality, and to develop 
instruments that measure those universal constructs (etic perspective); or (b) another that 
regards culture as an inseparable factor in the development of individuals’ characteristics, 
and argues in favor of creating instruments that are culture-specific (emic perspective) 
(Dana, 1988; see Helfrich, 1999, for a more complete discussion on the etic-emic 
controversy).  
Undoubtedly, both methods have limitations and can not easily resolve the 
challenges of multicultural and cross-cultural assessment. While the emic approach 
seems ideal in that it emphasizes the need for understanding individuals in their social 
context, it also implies the need for the development of an inordinate number of 
instruments for a given construct, one from within each existing culture. Aside from the 
enormous expense involved in the development of multiple tests, a major limitation of 
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this method is the fact that it makes it impossible for researchers and clinicians to 
compare an individual’s or cultural group’s performance cross-culturally (Samuda, 
1998). On the other hand, the etic approach also poses its own set of problems for 
assuming the existence of universal truths, which some argue may be too difficult to find 
or even impossible to separate from the always-present influence of culture in human 
behavior (van de Vijver & Poortinga, 1991; cited in Dana, 1988).  
MCMI Translations 
Despite the trend for developing culture-specific instruments (Dana, 1987; Dana, 
2000) and many methodological problems involved in the development of high quality 
test translations (Bracken & Barona, 1991; Butcher, 1996a; Geisinger, 1994; van de 
Vijver & Poortinga, 1991; van de Vijver & Hambleton, 1996), translations of 
psychological measures continue to be widely used and offer a less-than-ideal but 
functional solution to the challenges of multicultural assessment in the context of both 
cross-cultural research and culturally-sensitive clinical practice. Because the translation 
process of an instrument is a costly and time-consuming task, the literature advises that 
care should be exercised in selecting for translation only tests that are theoretically sound, 
psychometrically reliable, and demonstrate adequate validity in the original language.  
The MCMI clearly meets these criteria. In addition to being generally recognized 
as a reliable and valid instrument, the MCMI has a strong theoretical foundation. In his 
evolutionary and ecological theory of personality, Millon proposed that human behavior 
is directed by three “motivating aims,” which he defined as the bipolar dimensions of 
pleasure-pain, active-passive, and self-other (Millon, 1990; Millon, 1994; cited in 
Escovar, 1997). According to Millon, individual organisms are born with the potential for 
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developing certain traits based on their genetic makeup, but “over time the salience of 
these trait potentials become differentially prominent as the organism interacts with its 
environment” (Millon, 1990, p. 22). Although a full discussion of Millon’s theory is 
beyond the scope of this study, it is important to note that his model for understanding 
human behavior parallels similar models used to explain differences between cultural 
groups and has been recognized as having the potential for helping to elucidate cross-
cultural questions (Escovar, 1997).  
The literature indicates that several MCMI translations have been developed and 
are currently being used in many other countries (Groth-Marnat, 2003); however, with 
the exception of a translation into Dutch-Flemish developed for use in the Netherlands 
and Belgium (Luteijn, 1990; Mortensen & Simonsen, 1990; Sloore & Derksen, 1997), no 
other information was found regarding international applications of the MCMI.   
With regards to the Dutch-Flemish MCMI validity for diagnosing substance 
abuse, a study comparing patients’ scores on the translated MCMI and translated MMPI 
(N=52) found a correlation of .51 for the MCMI Alcohol Abuse scale and the MMPI 
McAndrew scale. A correlation of .58 was found for the MCMI Drug Abuse scale and 
the MMPI McAndrew scale (Sloore & Derksen, 1997).  
Purpose of the Study 
The purpose of this study was to provide a preliminary appraisal of the usefulness of 
the Brazilian-Portuguese version of the MCMI-III (BP-MCMI-III) for cross-cultural 
applications. More specifically, this study examined the validity of the BP-MCMI-III 
Alcohol Dependence and Drug Dependence scales for detecting substance 
abuse/dependence problems in a Brazilian sample composed of clinical and non-clinical 
 
 
 33
subjects. The focus was on evaluating the diagnostic validity of these scales by comparing 
participants’ group status (patients receiving substance abuse treatment versus controls) 
against diagnoses made on the basis of the test (Hypothesis 1 and Hypothesis 2), and by 
comparing diagnoses made on the basis of the DSM-IV-TR against diagnoses made on the 
basis of the test (Hypothesis 3 and 4). In addition, the construct validity of the Alcohol 
Dependence scale was examined by comparing the subjects’ scores on the BP-MCMI-III 
against scores on the AUDIT (Hypothesis 5). Because this investigator did not find a 
concurrent measure of drug abuse/dependence in Portuguese that could be used in this 
study, the concurrent validity of the Drug Dependence scale was not tested. 
Hypothesis 1 
It was expected that clinical subjects would have a significantly higher raw and base 
rate score than controls on the Alcohol Dependence scale of the Brazilian-Portuguese 
version of the Millon Clinical Multiaxial Inventory-III (BP-MCMI-III), when clinical and 
control groups were defined based on whether individuals were receiving or not receiving 
treatment for alcohol-related problems at the time of testing. 
Hypothesis 2 
It was expected that clinical subjects would have a significantly higher raw and base 
rate score than controls on the Drug Dependence scale of the Brazilian-Portuguese version 
of the Millon Clinical Multiaxial Inventory-III (BP-MCMI-III), when clinical and control 
groups were defined based on whether individuals were receiving or not receiving treatment 
for drug-related problems at the time of testing. 
 
 
 
 
 34
Hypothesis 3 
It was expected that individuals diagnosed with alcohol abuse or dependence based 
on DSM-IV-TR criteria would have a significantly higher raw and base rate score than 
controls on the Alcohol Dependence scale of the Brazilian-Portuguese version of the Millon 
Clinical Multiaxial Inventory-III (BP-MCMI-III). 
Hypothesis 4 
It was expected that individuals diagnosed with drug abuse or dependence based on 
DSM-IV-TR criteria would have a significantly higher raw and base rate score than controls 
on the Drug Dependence scale of the Brazilian-Portuguese version of the Millon Clinical 
Multiaxial Inventory-III (BP-MCMI-III). 
Hypothesis 5 
It was expected that there would be a significant positive correlation between 
participants’ scores on the Alcohol Dependence scale of the Brazilian-Portuguese version of 
the Millon Clinical Multiaxial Inventory-III (BP-MCMI-III) and scores on the Alcohol Use 
Disorders Identification Test (AUDIT).  
Post Hoc Analyses 
The following questions regarding indices of diagnostic validity were answered:  
(1) What is the sensitivity of the BP-MCMI-III Alcohol and Drug Dependence 
scales?  
(2) What is the specificity of the BP-MCMI-III Alcohol and Drug Dependence 
scales?  
(3) What is the Positive Predictive Power (PPP) of the BP-MCMI-III Alcohol and 
Drug Dependence scales?  
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(4) What is the Negative Predictive Power (NPP) of the BP-MCMI-III Alcohol 
and Drug Dependence scales? 
(5) What is the Overall Diagnostic Power (DxP) of the BP-MCMI-III Alcohol and 
Drug Dependence scales? 
(6) What is the Incremental Validity of Positive Test Diagnoses (IPPP) of the BP-
MCMI-III Alcohol and Drug Dependence scales? 
(7) What is the Incremental Validity of Negative Test Diagnoses (NPPP) of the 
BP-MCMI-III Alcohol and Drug Dependence scales? 
(8) What is the value of Cohen’s Kappa for the BP-MCMI-III Alcohol and Drug 
Dependence scales? 
(9) What is Cohen’s Effect Size for the BP-MCMI-III Alcohol and Drug 
Dependence scales? 
(10) What is the Area Under the ROC curve for the BP-MCMI-III Alcohol and 
Drug Dependence scales? 
Furthermore, diagnostic validity indices for the Brazilian version of the AUDIT 
used in this study were computed as they have not yet been reported in the literature. 
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CHAPTER III 
Method 
Participants 
Clinical Participants 
Clinical participants were contacted through two substance abuse treatment 
facilities in Rio de Janeiro, Brazil – Clínica Pater-Aldeia and Primeira Clínica Popular do 
Estado do Rio de Janeiro (see the Procedures section for details about how subjects were 
recruited). They were invited to participate in this study by responding anonymously to 
the assessment materials. All potential participants were fully informed about the purpose 
of the investigation, the procedures involved, the risks and benefits associated with their 
participation, and their right to withdraw from the study at any time. They were assured 
that their answers would be kept confidential and those who agreed to participate were 
asked to sign an Informed Consent Form (See Appendixes C and D). The criteria for 
inclusion were: (1) subject’s willingness to participate; (2) being above eighteen years of 
age; and (3) being in inpatient or outpatient treatment for alcohol/drug abuse or 
dependence at the time of testing.  
A total of 75 patients receiving substance abuse treatment responded to the 
assessment materials. Twenty-three patients were receiving treatment due to alcohol 
related disorders only, 12 due to drug related disorders only, and 40 had diagnoses of 
both alcohol and drug related problems. Clinical participants were mostly male, single, 
unemployed, and Catholic. Approximately 63% had completed a minimum of 8th grade 
level education. Patients’ age ranged from 18 to 60 (M = 37; SD = 10).  
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Non-Clinical Participants 
Non-clinical participants were contacted through two churches in Rio de Janeiro, 
Brazil – the Igreja Prebiteriana Betânia and the Igreja Congregacional de Vila Paraíso 
(see the Procedures section for details about how participants were recruited). They were 
fully informed about the purpose of the investigation, the procedures involved, the risks 
and benefits associated with their participation, and their right to withdraw from the study 
at any time. They were assured that their answers would be kept confidential and those 
who agreed to participate voluntarily were asked to sign an Informed Consent Form. The 
criteria for inclusion were: (1) subject’s willingness to participate; (2) being above 
eighteen years of age; (3) receiving no treatment for substance abuse at the time of 
testing; and (4) having no history of substance abuse treatment. The decision to recruit 
non-clinical participants through churches was based on this investigator’s relative easy 
access to this population through local contacts.  
The non-clinical sample was composed of 33 female and 18 male participants 
(N=51), with ages ranging from 19 to 67 years (M = 34; SD = 13). Most non-clinical 
participants identified themselves as members of the protestant church, were either single 
or married, and had completed a minimum of 8th grade education. Approximately 50% 
had either college or graduate degrees. With regards to occupation, only 6% were 
unemployed. Table 9 presents a detailed description of the clinical and non-clinical 
samples, as well as of sub-samples within the clinical group (patients with alcohol-related 
problems only, patients with drug-related problems only, and patients receiving treatment 
for both alcohol- and drug-related problems). 
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Table 9 
Demographic Information 
 Alcohol Only Drug Only Alcohol and 
Drug  
Total Clinical 
Sample 
Non-Clinical 
Sample 
 N = 23 N = 12 N = 40 N = 75 N = 51 
Age*       
Mean and (SD) 43 (8) 32 (9) 35 (9) 37 (10) 34 (13) 
       Range 19 – 57 18 – 48 19 – 60 18 – 60 19 – 67 
Gender*      
Male 19 9 31 59 18 
Female 4 3 9 16 33 
Marital Status**      
Single 11 6 19 36 26 
Married 8 3 9 20 22 
Widowed 1 0 1 2 0 
Separated/Divorced 3 3 10 16 3 
Occupation*      
Office 0 1 5 6 11 
Factory 3 0 2 5 0 
Professional 6 1 4 11 14 
Unemployed 8 7 16 31 3 
Other 6 3 13 22 23 
Education*      
Elementary Incomplete 2 1 4 7 0 
Elementary Complete 0 3 1 4 0 
Middle Incomplete 5 3 9 17 1 
Middle Complete 3 0 8 11 0 
High Incomplete 5 1 3 9 2 
High Complete 3 2 6 11 11 
College Incomplete 4 1 4 9 12 
College Complete 1 1 2 4 14 
Graduate Incomplete 0 0 3 3 2 
Graduate Complete 0 0 0 0 9 
Religion*      
None 2 1 8 11 0 
Protestantism 3 1 7 11 48 
Catholicism 13 7 15 35 2 
Spiritism 4 1 6 11 0 
Afro-Brazilian 0 1 3 4 0 
Other 1 1 1 3 1 
Alcohol Treatment Hx*      
Never 11 8 19 38 51 
1 – 2 times 9 4 13 26 0 
3 – 4 times 2 0 1 3 0 
> 4 times 1 0 7 8 0 
Drug Treatment Hx***      
Never 20 7 16 43 51 
1 – 2 times 2 3 12 17 0 
3 – 4 times 0 1 4 5 0 
> 4 times 0 0 7 7 0 
Frequency of Drinking**      
Never 0 7 2 9 31 
1 time per month or less 0 0 1 1 12 
2 – 4 times per month 0 3 1 4 5 
2 – 3 times per week 4 1 6 11 3 
4 or more times per week 19 0 30 49 0 
      
* N = 126; ** N = 125; *** N = 123 
 
 
 39
Control Groups 
The composition of clinical and control groups varied for each hypothesis. For 
testing hypothesis 1, the clinical group was composed of participants who were receiving 
treatment for alcohol-related problems only (N = 23) and those who were receiving 
treatment for both alcohol- and drug-related problems (N = 40) at the time of testing.  The 
control group was composed of non-clinical participants (N = 51).   
For hypothesis 2, the clinical group was composed of participants who were 
receiving treatment for drug-related problems only (N = 12) and those who were 
receiving treatment for both alcohol- and drug-related problems (N = 40) at the time of 
testing.  The control group was composed of non-clinical participants (N = 51).   
For hypothesis 3, the clinical group was composed of participants who were 
identified as having either an alcohol abuse or an alcohol dependence diagnosis according 
to DSM-IV-TR criteria (N = 66); the control group was composed of participants who did 
not meet DSM-IV-TR criteria for alcohol-related disorders (N = 60).  
For hypothesis 4, the clinical group was composed of participants who were 
identified as having either a drug abuse or a drug dependence diagnosis according to 
DSM-IV-TR criteria (N = 72); the control group was composed of participants who did 
not meet DSM-IV-TR criteria for drug-related disorders (N = 54).  
Statistical Differences Between Clinical and Control Groups 
Group equality was tested by performing chi-square tests on the following 
variables: gender, marital status, occupation, education, religion, alcohol treatment 
history, drug treatment history, and frequency of drinking. A t-test was used for testing 
equality in terms of age. The results indicated that the clinical and control groups (a) were 
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non-equivalent on all of these variables, except age, for hypothesis 1; (b) were non-
equivalent on all variables, except age, for hypothesis 2; (c) were non-equivalent on all 
variables, except marital status, for hypothesis 3; and (d) were non-equivalent on all 
variables, except age, for hypothesis 4. Tables 10 through 13 present the results of these 
tests.  
 
Table 10 
Tests of Group Equality on Demographic Variables for Hypothesis 1 (N = 114)  
Variable t / x2 Df P 
Age**   1.91 110 .059 
Gender 22.74 1 .000 
Marital Status*   8.18 3 .042 
Occupation 23.63 4 .000 
Education 49.47 9 .000 
Religion 70.28 5 .000 
Alcohol Treatment Hx 37.60 3 .000 
Drug Treatment Hx** 26.91 3 .000 
Frequency of Drinking 89.96 4 .000 
* N = 113; ** N = 112 
 
Table 11 
Tests of Group Equality on Demographic Variables for Hypothesis 2 (N = 103)  
Variable t / x2 Df P 
Age** .16 99 .874 
Gender 18.14 1 .000 
Marital Status* 10.21 3 .017 
Occupation 24.37 4 .000 
Education 46.64 9 .000 
Religion 65.57 5 .000 
Alcohol Treatment Hx 37.59 3 .000 
Drug Treatment Hx** 44.22 3 .000 
Frequency of Drinking* 53.12 4 .000 
* N = 102; ** N = 101 
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Table 12 
Tests of Group Equality on Demographic Variables for Hypothesis 3 (N = 126)  
Variable t / x2 Df  P 
Age** 2.24 122 .027 
Gender 21.48 1 .000 
Marital Status*   4.77 3 .190 
Occupation 12.89 4 .012 
Education 33.16 9 .000 
Religion 57.71 5 .000 
Alcohol Treatment Hx 21.28 3 .000 
Drug Treatment Hx*** 14.40 3 .002 
Frequency of Drinking*  99.94 4 .000 
* N = 125; ** N = 124; ** N = 123 
   
Table 13 
Tests of Group Equality on Demographic Variables for Hypothesis 4 (N = 126)  
Variable t / x2 Df P 
Age** .80 122 .423 
Gender 11.05 1 .001 
Marital Status* 10.96 3 .012 
Occupation 11.73 4 .019 
Education 27.61 9 .001 
Religion 38.16 5 .000 
Alcohol Treatment Hx 20.29 3 .000 
Drug Treatment Hx** 40.57 3 .000 
Frequency of Drinking*  20.92 4 .000 
* N = 125; ** N = 124; ** N = 123 
 
Data Collection Sites 
Clínica Pater-Aldeia 
The Pater-Aldeia Clinic is a privately owned substance abuse facility located in an 
upper-middle-class suburban area near the city of Rio de Janeiro. This clinic has been 
operating since 1990 and is staffed with a multidisciplinary clinical team that includes a 
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general physician, a psychiatrist, a counselor, a psychologist, an occupational therapist, 
and several nurses. The clinic provides residential treatment for up to 15 insured and 
private-pay patients with alcohol and/or drug problems. The minimum length of stay is 
30 days, with some patients staying up to 45 days. Approximately 13% of the clinical 
data (10 subjects) were collected at this site.  
Primeira Clínica Popular do Estado do Rio de Janeiro 
The Primeira Clínica Popular do Estado do Rio de Janeiro – First Popular Clinic 
of the State of Rio de Janeiro - provides inpatient and outpatient substance abuse 
treatment free of charge to low-income patients in the suburban city of Santa Cruz. The 
clinic is a non-governmental agency funded by the state and has been operating since 
2000. It is staffed with a multidisciplinary clinical team that includes several 
psychologists, physicians, occupational therapists, family therapists, social workers, 
nurses and health technicians. The clinic provides inpatient treatment for up to 90 patients 
with alcohol and/or drug problems. The typical length of stay is 40 to 45 days. After 
discharge, patients continue treatment on an outpatient basis for up to 9 months. 
Approximately 87% of the clinical data (65 subjects) were collected at this site. All 
participants were inpatients. 
Igreja Congregacional em Vila Paraíso 
With approximately 250 members, the Congregational Church of Vila Paraíso is a 
Protestant church located in a lower-middle-class suburban area near the city of Rio de 
Janeiro. Approximately 57% of the non-clinical data (29 participants) were collected at 
this site.  
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Igreja Presbiteriana Betânia 
Located in an upper-middle-class suburban area near the city of Rio de Janeiro, 
the Presbyterian Church Betânia is a Protestant church with approximately 400 members.  
Approximately 43% of the non-clinical data (22 participants) were collected at this site. 
Table 14 presents frequency and percentages of clinical and non-clinical participants by 
site. 
 
Table 14 
Frequency and Percentages of Clinical and Non-Clinical Participants by Site 
Sites Frequency % within Group % Total 
Clinical     
Pater-Aldeia Clinic 10 13.3 7.9 
Popular Clinic of Rio de Janeiro 65 86.7 51.6 
Clinical Total 75 100.0 59.5 
Non-Clinical     
Congregational Church 29 56.9 23.0 
Presbyterian Church 22 43.1 17.5 
Non-Clinical Total 51 100.0 40.5 
 
Instrumentation 
BP- MCMI-III Alcohol Dependence and Drug Dependence Scales 
The Brazilian-Portuguese MCMI-III is a paper and pencil inventory containing 
175 true-false items. Like the original MCMI-III, the BP-MCMI-III has a total of 27 
subscales: (a) three for estimating the individual’s test-taking attitude, (b) 14 for 
measuring different personality styles, and (c) 10 for assessing the presence of clinical 
syndromes, including anxiety, depression, psychotic disorders, posttraumatic stress, and 
substance-related problems (Millon, 1997).  
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The MCMI-III was translated by this investigator and other members of the 
research team using a combination of translation practices discussed in the literature, 
which included the use of a translation committee, the use of translation revisers, a 
backtranslation procedure, a bilingual test-retest pilot, and a final revision of the problem-
items (Bracken & Barona, 1991; Geisinger, 1994; Butcher, 1996a; Butcher, 1996b; Butcher 
& Hans, 1996; Sperber, Devellis, & Boehlecke, 1994; Van de Vijver, F., & Hambleton, 
R. K., 1996). All 15 items that comprised the original Alcohol Dependence scale and all 
14 items that comprised the original Drug Dependence scale remained in the translated 
version. No changes were made in the structure of the scales or in the content of the 
items. See Appendices E and F for more details on the scales’ composition and item 
weighing for the original and translated versions.  
High scores on the Alcohol Dependence scale are expected to be indicative of 
current problematic drinking or a history of alcoholism with associated symptoms such as 
subjective distress, family problems, and deficits in social and occupational functioning. 
Similarly, high scores on the Drug Dependence scale are expected to be indicative of 
current drug use or a history of drug addiction with associated symptoms (Craig, 1993). 
A reliability study with 220 Brazilian college students in Rio de Janeiro found test-retest 
coefficients of .70 and .85 for the BP-MCMI-III Alcohol Dependence and Drug 
Dependence scales, respectively (Magalhaes et al., 2004).  Please refer to Appendices A 
and B for a detailed description of the methodological procedures used for the translation 
of the MCMI-III into Brazilian-Portuguese and the results of preliminary studies. 
Due to the fact that the Portuguese language has gender-specific words, the 
development of gender-specific forms was deemed appropriate for use in the present study. 
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The BP-MCMI-III used in prior studies contained words in the masculine form only. The 
gender-specific forms that were used in this study were equal in content, but were expected 
to facilitate the readability of the items. The following are examples of items that were 
modified (gender-specific words are shown in bold).  
 
Item 18: 
a) Tenho receio de me aproximar de outra pessoa porque 
posso acabar sendo ridicularizado ou humilhado 
(masculine form). 
b) Tenho receio de me aproximar de outra pessoa porque 
posso acabar sendo ridicularizada ou humilhada 
(feminine form). 
Item 90: 
c) Às vezes fico confuso e me sinto perturbado quando as 
pessoas são gentis comigo (masculine form). 
d) Às vezes fico confusa e me sinto perturbada quando as 
pessoas são gentis comigo (feminine form). 
 
Diagnostic Questionnaire 
A diagnostic questionnaire was used to determine the presence or absence of 
substance abuse disorders according to the DSM-IV-TR criteria. This questionnaire is a 
self-report symptom checklist that contains 11 yes-no questions about substance use 
patterns, each corresponding to a specific diagnostic criterion listed under the DSM-IV-
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TR diagnostic code. Separate forms for alcohol and drug abuse/dependence were 
available. 
Structured diagnostic interviews are commonly used in substance abuse research 
and are generally considered reliable instruments for use with both clinical samples and 
the general population (Grant and Towle, 1990; Grant, 1997). The diagnostic instrument 
that was used in this study is a reduced version of the Alcohol Use Disorder and 
Associated Disabilities Interview Schedule (AUDADIS), one of the most widely used 
diagnostic instruments of this type. The AUDADIS operationalized the DSM-IV criteria 
for alcohol abuse and dependence and relies exclusively on respondent self-report (Grant, 
1992). A study with the AUDADIS found the combined diagnoses of lifetime alcohol 
abuse and dependence to be highly reliable (Grant, Harford, Dawson, Chou, and 
Pickering, 1995). 
The translation of this instrument into Brazilian-Portuguese was completed by this 
investigator, with the assistance of a professional translator. The translated version was 
then backtranslated into English by a bilingual research assistant (Brazilian native) and 
compared with the original version by a monolingual English speaker (American native).  
No major discrepancies were found between the two English versions and only minimal 
changes were made on the final Brazilian-Portuguese version that was used in this study. 
Diagnoses made on the basis of this questionnaire were compared against diagnoses 
made on the basis of the BP-MCMI-III to test this study’s primary hypotheses (3 and 4) 
and to calculate diagnostic efficiency indices for both substance dependence scales of the 
BP-MCMI-III. Appendices G and H present the English and Portuguese versions.  
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Brazilian-Portuguese Version of the Alcohol Use Disorders Identification Test 
The Alcohol Use Disorders Identification Test (AUDIT) was developed by the 
World Health Organization (WHO) in a six-country collaborative project for early 
detection of problem drinking, as part of a brief intervention trial (Saunders & Aasland, 
1987). The instrument has been recognized as a highly sensitive measure that has the 
advantage of detecting hazardous drinking separate from alcohol dependence, a feature 
that is considered an improvement over other screening questionnaires that were 
available at the time of its development. Unlike the MCMI-III Alcohol Dependence scale, 
which assesses drinking problems in the context of general psychopathology, the AUDIT 
was developed specifically for the detection of problem drinking in primary care settings, 
where hazardous drinkers seek medical treatment for other health-related concerns 
(Saunders, Aasland, Babor, De La Fuente, & Grant, 1993; Miles, Winstock, & Strang, 
2001; Maisto, S. A., Conigliaro, J., McNeil, M., Kraemer, K., & Kelley, M. E., 2000; 
Allen, Litten, Fertig, & Babor, 1997; Fleming, Barry, & MacDonald, 1991). Another 
important and unique feature of the AUDIT is the fact that its developers were careful to 
select items that were conceptually and empirically valid cross-culturally. Items were 
derived from a large cross-national data set (N = 1888) and checks were made to ensure 
that none performed poorly in any individual national sample. Participating nations were 
Australia, Bulgaria, Kenya, Mexico, Norway and the United States (Saunders, Aasland, 
Babor, De La Fuente, & Grant, 1993).  
The AUDIT is a paper and pencil “yes-no” questionnaire composed of 10 items 
related to alcohol consumption patterns – three questions on the amount and frequency of 
drinking, three questions on harmful use of alcohol, and four on alcohol-related 
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consequences – and scores ranging from 0 to 40. Different cut-off scores have been 
suggested in the literature. The original 1987 study conducted by the WHO 
recommended a score of 11 or more as indicative of a drinking problem (Babor, T., 
Korner, P., & Wilber, C., 1987; cited in Fleming, Barry, & MacDonald, 1991), but other 
studies have used a cut-off score of 8 (Reinert & Allen, 2002; Conigrave, Hall, & 
Saunders, 1995; Maisto, S. A., Conigliaro, J., McNeil, M., Kraemer, K., & Kelley, M. E., 
2000).  
In a review of the AUDIT literature (English language version), Reinert and Allen 
(2002) reported that the instrument has proven to be internally consistent with diverse 
samples and in different settings, with median Chronbach’s alpha falling in the .80s for 
the 18 studies included in the review. The four studies that tested the temporal reliability 
of the English AUDIT over a two-week interval found results ranging from .64 to .92. 
The median sensitivity was .86 and the median specificity was .89 for a cut-off score of 
8, across 13 studies.  
When researching for a Brazilian-Portuguese translation of the AUDIT to be used 
in this study, three were found. The first, by Figlie’s research team, was used in a 
published study that looked at the frequency of smoking and problem drinking among 
general hospital inpatients in Sao Paulo, Brazil (Figlie, Pillon, Dunn & Laranjeira, 2000). 
In personal correspondence with the author (Figlie, 2004), Figlie reported that the 
reliability and validity of her translation was not tested, but graciously provided copy of 
an unpublished Masters thesis on a different translation of the AUDIT, developed by one 
of her colleagues (Méndez, 1999). Méndez developed a more systematic translation and 
tested its validity against diagnoses of alcohol abuse made on the basis of the ICD-10 
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criteria. His total sample was composed of 733 participants (486 had at least one drink in 
the past 12 months) recruited through two primary care facilities – a hospital and an 
outpatient clinic that serve low-income communities in the outskirts of Pelotas, southern 
Brazil. For a cut-off score of 8, sensitivity was .92 and specificity was .62. In order to 
improve specificity while keeping sensitivity within an acceptable level, Méndez 
suggested the use of a cut-off score of 10 (sensitivity = .88; specificity = .80). Table 15 
shows validity indices for cut-off scores of 8, 10, 11, 12, 14 and 16.   
 
 
Table 15 
Validity Indices of the Brazilian-Portuguese AUDIT for Diagnosing Alcohol Abusea
 Cut-off Scores 
 8 10 11 12 14 16 
Sensitivity .92 .88 .84 .84 .74 .65 
Specificity .62 .80 .84 .86 .92 .94 
Accuracy .68 .82 .84 .86 .88 .89 
Positive Predictive Power .35 .49 .53 .57 .66 .71 
Negative Predictive Power .97 .97 .96 .96 .94 .93 
Classification Error .32 .18 .16 .14 .12 .11 
aMéndez (1999) 
 
More recently, a revision of Méndez’s translation was developed by Erikson 
Furtado’s research team in São Paulo, Brazil, in collaboration with the WHO and 
researchers associated with the University of Connecticut. The Connecticut group is 
working under the leadership of Thomas Babor, one of the principal investigators 
involved in the development of the original AUDIT. In personal correspondence with 
Furtado (May 3, 2004), he reported that his new Portuguese version was developed with 
the objective of incorporating the most current changes made on the international version 
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of the AUDIT. His research group also produced a translation and adaptation of the 
AUDIT manual and the Brief Interventions manual released by the WHO in 2001 (Babor, 
Higgins-Biddle, Saunders & Monteiro, 2001; Babor & Higgins-Biddle, 2001).  
When comparing the two versions, Furtado’s differs from Méndez’s in two ways: 
(1) less formal use of the Portuguese language; and (2) modifications in the number of 
standard-drinks for the question in item number 2 and the answer options in item number 
3, to accommodate for differences in the amount of alcohol contained in typical Brazilian 
drinks (Furtado, 2004). Furtado reported that his team has not yet tested the reliability 
and validity of his revised Portuguese AUDIT but does not anticipate that he will find 
major differences from results obtained with Méndez’s version. Although it is likely that 
the revised instrument remains valid, it is possible however that the changes made in the 
number of standard-drinks for items 2 and 3 will affect the operational characteristics of 
the instrument and, consequently, the selection of appropriate cut-off scores.  
Despite the lack of new validity data to support the revised translation, five 
factors influenced this investigator’s decision to use Furtado’s version in this study: (1) it 
was developed in collaboration with the original developers of the test, (2) it is up-to-date 
with the most current AUDIT manual, (3) the wording of the questions is more casual 
and more appropriate for the location where the data will be collected, (4) items were 
adapted to account for differences in the amount of alcohol contained in typical Brazilian 
drinks, and (5) cut-off scores will not be needed for analysis (total scores will be used). 
See Appendix I for the AUDIT in English and Appendix J for the Portuguese version that 
was used in this study.  
 
 
 
 51
Demographic Questionnaire 
The demographic questionnaire gathered information about the subjects’ age, 
gender, marital status, education, religion, occupation, history of substance abuse 
treatment, and reason for current admission to a substance abuse treatment facility. 
Information obtained with this questionnaire provided a description of the sample and 
determined group eligibility for hypotheses 1 and 2. See Appendix K. 
Procedure 
Training of Research Assistants 
Because the principal investigator was residing in the United States when this 
study was carried out, one data collection coordinator and four research assistants were 
involved in the recruitment and administration of the assessment measures to participants 
in Brazil. The data collection coordinator was responsible for overseeing the 
implementation of the data collection procedures and ensuring consistency with the 
research protocol. The coordinator had a Masters degree in mental health counseling 
from Florida Atlantic University and was a licensed mental health counselor by the 
Florida Department of Health with over 10 years of clinical experience. She was provided 
with a copy of the research proposal, which included information about the purpose, 
theoretical basis and methods of the study, as well as specific instructions for instrument 
administration (see Appendix L).  
The research assistants worked under the coordinator’s supervision and were 
responsible for assisting her in all aspects of the data collection procedure. Three of them 
had graduate degrees (in education, marketing, and vocational counseling) and had 
experience with data collection prior to their collaboration with this study. One was 
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completing a college degree in economy.  
The coordinator and assistants were trained by the principal investigator during a 
trip to Rio de Janeiro. The training consisted of two 2-hour meetings, during which the 
coordinator and assistants (a) were provided with a detailed explanation of the purpose of 
the study and all procedures involved in data collection, (b) were asked to complete all 
assessment measures to become familiar with the research protocol, and (c) were 
encouraged to ask questions and voice concerns about potential problems with the 
recruitment of subjects and the administration of the protocols. In addition, the 
coordinator and research assistants were supervised by the principal investigator during 
their first administration of the assessment materials. They maintained regular 
communication with the principal investigator by phone and e-mail during the entire data 
collection phase to discuss any problems with the recruitment of subjects and instrument 
administration.   
Initially the research assistants were involved only in the recruitment and testing 
of controls, but later participated in data collection at the substance abuse treatment 
facilities as well, due to the coordinator being unable to continue her direct collaboration 
with this project.  
Data Collection 
Clinical Sample  
Contact with program directors of the Clínica Pater-Aldeia and Primeira Clínica 
Popular do Estado do Rio de Janeiro was made by this investigator. A written 
authorization for data collection was obtained prior to the recruitment of the subjects and 
administration of the assessment measures.  
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During group therapy sessions, patients were made aware of this study by their 
own therapists, who asked for their voluntary and anonymous participation. All potential 
subjects were fully informed about the purpose of the investigation, the procedures 
involved, the risks and benefits associated with their participation, and their right to 
withdraw from the study at any time. They were assured that their answers would be kept 
confidential and those who agreed to participate were asked to sign an Informed Consent 
Form.  
Patients who agreed to participate in the study stayed in the group room after their 
therapy session ended to complete the assessment materials. The instruments were 
administered by either the data collection coordinator or one of the research assistants. 
Even though data collection was performed outside of the United States, where the 
Health Insurance Portability and Accountability Act (HIPAA) does not apply, attention 
was paid to methods that insured patients’ privacy.  
Non-Clinical Sample 
Contact with leaders of the Igreja Congregacional em Vila Paraíso and the Igreja 
Presbiteriana Betânia in Rio de Janeiro was made by this investigator. A written 
authorization for data collection was obtained.  
During regular church meetings, a brief announcement about the study was made 
by the church leader and those interested in participating were instructed to meet with one 
of the research assistants for additional information. Those who decided to meet with the 
research assistants were fully informed about the purpose of the investigation, the 
procedures involved, the risks and benefits associated with their participation, and their 
right to withdraw from the study at any time. They were assured that their answers would 
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be kept confidential and those who agreed to participate were asked to sign an Informed 
Consent Form. Participants were then given the option to complete the assessment 
materials at that time or schedule an appointment to meet with the research assistants at 
another date.  
All Participants 
All participants, regardless of group membership, were administered the following 
assessment measures: (1) the Brazilian-Portuguese version of the third edition of the Millon 
Clinical Multiaxial Inventory (BP-MCMI-III), (2) the Brazilian-Portuguese version of the 
Alcohol Use Disorders Identification Test (AUDIT), (3) a diagnostic questionnaire 
(DSM-IV-TR), and (4) a demographic questionnaire.  
Testing was typically done in groups of 5 to 10 participants and subjects were 
administered the assessment materials in counterbalanced order to control for possible 
order effects. Approximately half of the sample completed the assessment measures in 
the following order: demographic questionnaire, BP-MCMI-III, diagnostic questionnaire, 
and AUDIT. The other half completed the assessment measures in the following order: 
demographic questionnaire, diagnostic questionnaire, AUDIT, and BP-MCMI-III.  
The examiners followed the standard administration procedures (Appendix L) 
with all subjects, except when participants did not have at least an 8th grade education (N 
= 29). In those cases, examiners read the instructions and all questions to every one in the 
group and waited until all participants had answered each question before moving to the 
next. Standard administration involved reading the instructions and the first two questions 
of each instrument to ensure that participants understood how to complete the measures, 
and allowing them to complete the remaining questions at their own pace (N = 97). 
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Participants who did not have at least an 8th grade education were mostly patients at the 
First Popular Clinic of the State of Rio de Janeiro (26 participants), 2 were patients at the 
Pater-Aldeia Clinic, and 1 was recruited through the Igreja Congregacional em Vila 
Paraiso.  
For testing the effect of procedure differences on the subjects’ test scores, 4 t-tests 
were run using a dummy-coded education variable (1 = 8th grade education and above; 0 
= below 8th grade education) as the independent variable. The dependent variables were 
the subjects’ raw and base rate scores on the Alcohol Dependence and Drug Dependence 
scales of the BP-MCMI-III. Because most participants who did not have a minimum of 
8th grade education (97 percent of the total sample) were part of the clinical sample, only 
clinical subjects were used for this comparison. The results were not significant, 
indicating that procedure differences did not have an effect on the dependent variables. 
Table 16 presents the results of the t-tests.  
 
Table 16 
Effect of Procedure Differences on the Dependent Variables 
Variable t Df p 
Alcohol Dependence: Raw    .52 73 .602 
Drug Dependence: Raw 1.66 73 .102 
Alcohol Dependence: Base Rate     .31 73 .754 
Drug Dependence: Base Rate   1.18 73 .240 
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CHAPTER IV 
Results 
Preliminary Analyses 
Effect of Test Order 
Robust t-tests were used to examine the effect of test order on the dependent 
variables. The results obtained were non-significant for both the Alcohol Dependence and 
the Drug Dependence scales, indicating that the order by which the tests were completed 
by the participants did not affect their BP-MCMI-III scores. Table 17 presents the results 
of these tests. 
    
Table 17 
Effect of Test Order on the Dependent Variables (N = 126) 
Variable t df p 
Alcohol Dependence: Raw   .46 123.94 .644 
Drug Dependence: Raw 1.12 122.78 .265 
Alcohol Dependence: Base Rate 1.11 121.75 .270 
Drug Dependence: Base Rate  1.03 123.77 .305 
 
Correlation between the Dependent Variables 
Pearson correlations between the BP-MCMI-III Alcohol Dependence and Drug 
Dependence scales were calculated. For raw scores, the correlation was .85; and for base 
rate scores it was .73. They were both found to be significant at the .01 level (two-tailed).  
Effect of the Demographic Variables on the Dependent Variables 
As noted in the methods section, clinical and control groups were unequal on all 
demographic variables (except age for hypotheses 1, 2 and 4; and marital status for 
hypothesis 3). If the relationship between the demographic variables and the dependent 
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variables are statistically significant, this could pose a threat to the internal validity of the 
study.  
Pearson correlations between the subjects’ BP-MCMI-III scores on the Alcohol 
Dependence and Drug Dependence scales were run with the demographic variables to 
determine the need for statistically controlling their effect during hypotheses testing. 
Nominal variables were converted into dummy-coded variables to allow correlations to 
be computed [(1 = Protestant; 0 = other) for religion; (1 = married; 0 = other) for marital 
status; and (1 = employed; 0 = unemployed) for occupation].  Correlations were found to 
be significant for Gender, Marital Status, Education, Religion, History of Alcohol 
Treatment, History of Drug Treatment, and Frequency of Drinking. Table 18 presents the 
correlations for both raw and base rate BP-MCMI-III scores.  
 
Table 18 
Correlations between the Subjects’ Raw and Base Rate Scores on the BP-MCMI-III 
Substance Dependence Scales with Demographic Variables 
Variable Alcohol/Raw Drug/Raw Alcohol/BR Drug/BR 
Age .04 .09 .05 .16 
Gender .35** .40** .32** .26** 
Marital Status .17 .23* .18* .28** 
Occupation .13 .13 .13 .11 
Education .55** .55** .52** .47** 
Religion .67** .67** .63** .61** 
Alcohol Tx Hx .45** .45** .38** .39** 
Drug Tx Hx .39** .47** .34** .41** 
Frequency of Drinking .71** .60** .65** .57** 
*. Correlation is significant at the .05 level (2-tailed) 
**. Correlation is significant at the .01 level (2-tailed) 
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Hypotheses Testing 
The analysis of covariance (ANCOVA) is a statistical test that can be used when 
there is need for elimination of systematic bias (Stevens, 1990), as is the case in this 
study. For testing hypotheses 1, 2, 3 and 4, eight analyses of covariance (ANCOVAs) 
were run using gender, education, history of alcohol treatment, history of drug treatment, 
frequency of drinking, and dummy coded variables for marital status (1 = married; 0 = 
other) and religion (1 = Protestant; 0 = other) as covariates. The independent variables for 
each analysis were dichotomous (two groups = clinical, control) and the dependent 
variables were the BP-MCMI-III raw and base rate scores for the Alcohol Dependence 
and Drug Dependence scales. Hypothesis 5 was tested by performing a t-test to determine 
the significance of the correlation between AUDIT scores and BP-MCMI-III scores.  
Hypothesis 1 
It was expected that clinical participants would have a significantly higher raw and 
base rate score than controls on the Alcohol Dependence scale of the Brazilian-Portuguese 
version of the Millon Clinical Multiaxial Inventory-III (BP-MCMI-III), when clinical and 
control groups were defined based on whether individuals were receiving or not receiving 
treatment for alcohol-related problems at the time of testing. 
The diagnostic validity of the BP-MCMI-III Alcohol Dependence scale was 
supported by the results of the ANCOVAs when both raw (F = 18.19; df = 1, 111; p < 
.05) and base rate scores (F = 7.79; df = 1, 111; p < .05) were used in the analyzes. The 
scores of patients receiving treatment for alcohol-related problems at the time of testing 
(N = 60) were significantly higher than the scores of non-clinical participants (N = 51). 
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The magnitude of the effect (partial eta squared) reached .15 for raw and .07 for base rate 
scores.   
Hypothesis 2 
It was expected that clinical participants would have a significantly higher raw and 
base rate score than controls on the Drug Dependence scale of the Brazilian-Portuguese 
version of the Millon Clinical Multiaxial Inventory-III (BP-MCMI-III), when clinical and 
control groups were defined based on whether individuals were receiving or not receiving 
treatment for drug-related problems at the time of testing. 
The diagnostic validity of the BP-MCMI-III Drug Dependence scale was also 
supported by the results of the ANCOVAs when both raw (F = 70.38; df = 1, 99; p < .05) 
and base rate scores (F = 23.51; df = 1, 99; p < .05) were used in the analyzes. The scores 
of patients receiving treatment for drug-related problems (N = 48) were significantly 
higher than the scores of non-clinical participants (N = 51). The magnitude of the effect 
(partial eta squared) reached .44 for raw and .21 for base rate scores.   
Hypothesis 3 
For hypothesis 3, groups were defined based on the presence of positive (clinical) 
versus negative (control) DSM-IV-TR diagnoses. Subjects who gave 3 or more “yes” 
responses for items 1 through 7 of the Diagnostic Questionnaire (alcohol use questions) 
met the DSM-IV-TR diagnostic criteria for alcohol dependence; those who gave 1 or 
more “yes” responses for items 8 through 11 met criteria for alcohol abuse (see Appendix 
J). It was expected that individuals diagnosed with alcohol abuse or dependence based on 
DSM-IV-TR criteria would have significantly higher raw and base rate scores than controls 
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on the Alcohol Dependence scale of the Brazilian-Portuguese version of the Millon Clinical 
Multiaxial Inventory-III (BP-MCMI-III). 
The diagnostic validity of the BP-MCMI-III Alcohol Dependence scale was also 
supported by the results of the ANCOVAs when group eligibility was defined by the 
presence of positive versus negative DSM-IV-TR diagnoses, for both raw (F = 10.24; df 
= 1, 121; p < .05) and base rate scores (F = 6.98; df = 1, 121; p < .05). Participants who 
scored positive for alcohol-related problems on the Diagnostic Questionnaire (DQ) 
obtained higher raw and base rate scores on the BP-MCMI-III Alcohol Dependence scale 
than those who scored negative on the DQ. The magnitude of the effect (partial eta 
squared) reached .08 for raw and .06 for base rate scores.   
Hypothesis 4 
For hypothesis 4, groups were also defined based on the presence of positive 
(clinical) versus negative (control) DSM-IV-TR diagnoses. Subjects who gave 3 or more 
“yes” responses for items 1 through 7 of the Diagnostic Questionnaire (drug use 
questions) met the DSM-IV-TR diagnostic criteria for drug dependence; those who gave 
1 or more “yes” responses for items 8 through 11 met criteria for drug abuse (see 
Appendix J). It was expected that individuals diagnosed with drug abuse or dependence 
based on DSM-IV-TR criteria would have a significantly higher raw and base rate score 
than controls on the Drug Dependence scale of the Brazilian-Portuguese version of the 
Millon Clinical Multiaxial Inventory-III (BP-MCMI-III). 
The diagnostic validity of the BP-MCMI-III Drug Dependence scale was also 
supported by the results of the ANCOVAs when group eligibility was defined by the 
presence of positive versus negative DSM-IV-TR diagnoses, for both raw (F = 61.83; df 
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= 1, 121; p < .05) and base rate scores (F = 22.99; df = 1, 121; p < .05). Participants who 
scored positive for drug-related problems on the Diagnostic Questionnaire (DQ) obtained 
higher raw and base rate scores on the BP-MCMI-III Drug Dependence scale than those 
who scored negative on the DQ. The magnitude of the effect (partial eta squared) reached 
.36 for raw and .17 for base rate scores.  Table 19 summarizes the results of the 
ANCOVAs for hypotheses 1 through 4. 
 
Table 19 
Results of the ANCOVAs for Hypotheses 1 through 4   
 F p η² 
 Raw 
Scores 
Base 
Rates 
Raw 
Scores 
Base 
Rates 
Raw 
Scores 
Base 
Rates 
Hypothesis 1 18.19 7.79 .000 .006 .15 .07 
Hypothesis 2 70.38 23.51 .000 .000 .44 .21 
Hypothesis 3 10.24 6.98 .002 .009 .08 .06 
Hypothesis 4 61.83 22.99 .000 .000 .36 .17 
 
Hypothesis 5 
It was expected that there would be a significant positive correlation between 
subjects’ scores on the Alcohol Dependence scale of the Brazilian-Portuguese version of the 
Millon Clinical Multiaxial Inventory-III (BP-MCMI-III) and scores on the Alcohol Use 
Disorders Identification Test (AUDIT).  
Pearson correlations between the AUDIT and the BP-MCMI-III Alcohol 
Dependence scale were obtained using both raw (r = .81) and base rate scores (r = .72). 
The results showed strong positive correlations that were significant at the .01 level. 
Findings indicate that these two scales are measuring similar constructs and support the 
construct validity of the BP-MCMI-III Alcohol Dependence scale. 
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Post Hoc Analyses 
Validity Indices of the BP-MCMI-III Alcohol and Drug Dependence Scales 
Diagnostic validity indices were computed for the BP-MCMI-III Alcohol 
Dependence and Drug Dependence scales at cut-offs of 75, 80 and 85. The presence of 
positive versus negative DSM-IV-TR diagnoses, determined by the subjects’ scores on 
the Diagnostic Questionnaire, was considered the “gold standard” to which diagnoses 
made by the BP-MCMI-III were compared. Table 20 presents the number of positive and 
negative cases determined by the DSM-IV-TR criteria (true positives and true negatives) 
and the number of positive and negative cases identified by the BP-MCMI-III (test 
positives and test negatives).  
 
Table 20 
Diagnoses made by the DSM-IV-TR Criteria and by the BP-MCMI-III 
 DSM-IV-TR BP-MCMI-III  
(BR 75) 
BP-MCMI-III  
(BR 80) 
BP-MCMI-III  
(BR 85) 
 Positive Negative Positive Negative Positive Negative Positive Negative 
Alcohol 66 60 73 53 59 67 51 75 
Drug 54 72 53 73 46 80 39 87 
 
Conceptual formulas used to calculate sensitivity, specificity, positive predictive 
power (PPP), negative predictive power (NPP), overall diagnostic power (DxP) and 
prevalence of the BP-MCMI-III substance dependence scales are presented on Table 21.  
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Table 21 
Conceptual Formulas for Calculating the Operating Characteristics of a Testa
 Disorder  
Test Result Present Absent  
Positive A B A + B 
Negative C D C + D 
Totals A + C B + D N 
Index Definitionb Formula 
Sensitivity Pr (Test + │ Disorder +) A / (a + c) 
Specificity Pr (Test  - │Disorder - ) D / (b + d) 
Positive Predictive Power Pr (Disorder +│ Test + ) A / (a + b) 
Negative Predictive Power Pr (Disorder - │ Test - ) D / (c + d) 
Overall Diagnostic Power Proportion correctly classified (a + d) / N 
Prevalence Proportion of subjects with the disorder (a + c) / N 
a In Gilbertini et al. (1986). 
b Definitions are expressed in terms of conditional probabilities. The definitions for sensitivity would read: 
“the probability that the test is positive given the disorder is present.” 
 
Incremental validities for positive test diagnoses (IPPP) were defined as the 
difference between the Alcohol Dependence and Drug Dependence scales’ positive 
predictive powers and the prevalence of alcohol and drug problems in the sample, 
respectively. Incremental validities for negative test diagnoses (NPPP) were defined as 
the difference between the Alcohol Dependence and Drug Dependence scales’ negative 
predictive powers and their corresponding prevalence. Kappa values were determined by 
finding the proportion of agreements (adjusted for chance agreements) between BP-
MCMI-III and DSM-IV-TR classifications. Additional validity indices that can be 
calculated independently from cut-off scores – Effect Size and the area under the ROC 
curve (AUC) – were also computed. The results are summarized on Table 22. 
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Table 22 
Diagnostic Validity Indices of the BP-MCMI-III Alcohol Dependence and Drug 
Dependence Scales at 75, 80 and 85 Cut-Offs 
 Alcohol Dependence Scale Drug Dependence Scale 
 BR 75 BR 80 BR 85 BR 75 BR 80 BR 85 
Sensitivity .94 .80 .71 .82 .72 .65 
Specificity .82 .90 .93 .88 .90 .96 
PPP .85 .90 .92 .83 .85 .90 
NPP .93 .81 .75 .86 .81 .78 
DxP .88 .85 .82 .85 .83 .82 
IPPP .33 .38 .40 .40 .42 .47 
INPP .41 .29 .23 .43 .38 .35 
Kappa .76 .70 .64 .69 .64 .62 
Prevalence .52 .52 .52 .43 .43 .43 
Effect Size 1.89 1.89 1.89 1.90 1.90 1.90 
AUC .94 .94 .94 .94 .94 .94 
 
The area under ROC (receiver operating characteristic) curves, also known as 
AUC, was determined by plotting true positive rates against false positive rates of alcohol 
and drug problems at different cutoff points. Figure 1 and 2 provide a visual 
representation of AUC for both the Alcohol Dependence and Drug Dependence scales. 
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Figure 1: AUC for the Alcohol Dependence Scale of the BP-MCMI-III 
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Figure 2: AUC for the Drug Dependence Scale of the BP-MCMI-III 
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Validity Indices of the Brazilian AUDIT 
The operating characteristics of the revised translation of the AUDIT used in this 
study were not previously reported in the literature. Validity indices were calculated with 
this sample (N = 126). The results are presented on Table 23.  
 
Table 23 
Operating Characteristics of the Revised Brazilian AUDIT at 7, 8, 9 and 10 Cut-Offs 
 AUDIT Cut-Scores 
 7 8 9 10 
Sensitivity .95 .95 .95 .92 
Specificity .93 .95 .97 .97 
PPP .94 .95 .97 .97 
NPP .95 .95 .95 .92 
DxP .94 .95 .96 .94 
IPPP .42 .44 .45 .45 
INPP .43 .44 .44 .41 
Kappa .89 .91 .92 .89 
Prevalence .52 .52 .52 .52 
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Figure 3: AUC for the Revised Brazilian AUDIT 
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CHAPTER V 
Discussion 
Hypotheses 
This study examined the validity of the Brazilian-Portuguese version of the Millon 
Clinical Multiaxial Inventory-III (BP-MCMI-III) Alcohol Dependence and Drug 
Dependence scales for detecting alcohol- and drug-related problems in a Brazilian sample 
composed of clinical and non-clinical subjects.  
It was hypothesized that clinical participants would obtain significantly higher raw 
and base rate scores than controls on the Alcohol Dependence scale of the BP-MCMI-III 
when groups were defined based on two criteria: (a) whether individuals were receiving or 
not receiving treatment for alcohol-related problems at the time of testing (Hypothesis 1), 
and (b) whether they met the DSMI-IV-TR criteria for either alcohol abuse or dependence 
(Hypothesis 3).  
It was also hypothesized that clinical participants would obtain significantly higher 
raw and base rate scores than controls on the Drug Dependence scale of the BP-MCMI-III 
when groups were defined based on: (a) whether individuals were receiving or not receiving 
treatment for drug-related problems at the time of testing (Hypothesis 2), and (b) whether 
they met the DSM-IV-TR criteria for either drug abuse or dependence (Hypothesis 4).  
Furthermore, it was expected that there would be a significant positive correlation 
between participants’ scores on the Alcohol Dependence scale of the BP-MCMI-III and 
scores on the Alcohol Use Disorders Identification Test (AUDIT) (Hypothesis 5).  
All hypotheses were supported by the data. Findings indicated that the BP-
MCMI-III Alcohol Dependence scale can identify Brazilians with alcohol-related 
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disorders among those who do not have problems related to alcohol consumption; and 
that the BP-MCMI-III Drug Dependence scale can identify Brazilians with drug-related 
disorders among those who do not have problems related to drug usage. Furthermore, a 
high correlation between the BP-MCMI-III alcohol dependence scale and the AUDIT 
was found, which provides additional support for the validity of this scale. 
Diagnostic Validity Indices 
Base Rate scores for the MCMI-III are anchored to the prevalence rate of 
disorders in the psychiatric population. Prevalence rates obtained with the clinical sample 
used in the development phase of the instrument, as well as information derived from 
various epidemiological studies in the United States, were used to develop the criteria 
utilized to create the base rate scores for the original MCMI-III. As they apply to the 
clinical syndrome scales, cut-off scores of 75 and above on the MCMI-III indicate the 
presence of a syndrome; while scores of 85 and above indicate the prominence of a 
syndrome.  
The sample used in the present study was homogeneous when compared to the 
hundreds of participants with various psychiatric disorders that were included in the 
sample utilized for the development of the MCMI-III. Given the fact that prevalence was 
.52 for alcohol-related problems and .43 for drug related-problems in the present sample, 
these indices are likely to be non-representative of the prevalence of substance abuse 
disorders in the Brazilian psychiatric population at large and, therefore, inappropriate for 
deriving new base rate scores for the BP-MCMI-III.  
Without computing new base rates for the BP-MCMI-III, we can say that a 75 
cut-off for these scales is perhaps the most effective cut-score given this sample. At the 
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cut-score of 75, the BP-MCMI-III alcohol and drug dependence scales performed 
approximately equal or better than the MCMI-III (at cut-score of 85) for most validity 
indices when the 1994 MCMI-III data set was used for comparison. The BP-MCMI-III 
alcohol and drug dependence scales performed approximately equal or somewhat worse 
than the MCMI-III (at cut-score of 85) for most validity indices when the 1997 MCMI-III 
data set was used for comparison. These results are not surprising given the fact that there 
is concern about the possibility of underestimation of the validity of the MCMI-III based 
on the 1994 validity data and the potential for overestimation based on the 1997 data set 
(Hsu, 2002). A more detailed discussion about the 1994 and 1997 MCMI-III validity 
studies of the MCMI-III can be found in the literature review section of this paper. Table 
24 and 25 present validity indices for the MCMI-III and the BP-MCMI-III at 75 and 85 
cut-offs. 
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Table 24 
Comparative Table of Validity Indices for the MCMI-III and BP-MCMI-III Alcohol 
Dependence Scales 
 MCMI-III BP-MCMI-III 
 1994a 1997a BR 75 BR 85 
Sensitivity .73** .80* .94 .71 
Specificity .86**  .82 .93 
PPP .42** .88*  .85 .92 
NPP .96**  .93 .75 
DxP   .88 .82 
IPPP   .30*** .71*** .33 .40 
INPP   .08***    .13*** .41 .23 
Kappa   .45***    .81*** .76 .64 
Prevalence .12** .17* .52 .52 
Effect Size 1.68*** 2.85*** 1.89 1.89 
AUC   .88*** .98*** .94 .94 
aStatistic calculated using cut-score of 85.  
*In Millon, 1997; **In Restlaff, 1996; and ***In Hsu, 2002. 
 
 
 Table 25 
Comparative Table of Validity Indices for the MCMI-III and BP-MCMI-III Drug 
Dependence Scales 
 MCMI-III BP-MCMI-III 
 1994 a 1997 a BR 75 BR 85 
Sensitivity .52** .82* .82 .65 
Specificity .95**  .88 .95 
PPP .47** .93* .83 .90 
NPP .96**  .87 .78 
DxP   .85 .82 
IPPP        .39***    .82*** .41 .47 
INPP .04***    .09*** .44 .36 
Kappa .47***    .86*** .69 .62 
Prevalence .08** .11* .43 .43 
Effect Size 1.67***  3.34*** 1.90 1.90 
AUC .88***    .99*** .94 .94 
aStatistic calculated using cut-score of 85.  
*In Millon, 1997; **In Restlaff, 1996; and ***In Hsu, 2002. 
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Sensitivity and Specificity 
Specificity values for the alcohol dependence and drug dependence scales were 
above .80. Sensitivity was above .90 for alcohol dependence and above .80 for drug 
dependence. This indicates that both scales were sensitive for detecting positive 
disordered cases in the sample, while being specific enough to identify as positive those 
cases that truly had substance abuse disorders. As noted in the literature review section, 
specificity and sensitivity are usually considered to be independent of the prevalence of 
the disorder in the sample; in other words, a test should identify the same proportion of 
disordered cases across samples. However, calculating these two indices requires that one 
knows which cases in the sample really have the disorder the instrument is supposed to 
detect.  
In the present study, true positive and true negative cases of alcohol- and drug-
related disorders were determined by the subjects’ scores on a self-report symptom 
checklist, which contained 11 yes-no questions about substance use patterns, each 
corresponding to a specific diagnostic criterion listed under the DSM-IV-TR diagnostic 
code. Separate forms for alcohol and drug abuse/dependence were used.  
This leads to a question regarding the reliability and validity of the DSM-IV-TR 
and of diagnostic criteria checklists for accurately diagnosing substance abuse disorders. 
Because there is much overlap between the so-called “mental disorders,” critics of the 
DSM argue that categorical systems are ineffective and can work optimally only when 
members of a diagnostic class are homogeneous, when there are clear boundaries 
between classes, and when different classes are mutually exclusive (APA, 1994). 
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Despite its limitations, the DSM classification system has been recognized as a 
major improvement over diagnostic methods that rely on a clinician’s subjective 
interpretation of presented symptoms. A major contribution of the DSM is the 
development of specific criteria for classification of disorders, which allowed for the 
development of structured diagnostic interviews and increased the reliability of diagnoses 
made across examiners (Spiegel, 2005).   
Structured diagnostic interviews are commonly used in substance abuse research 
and are generally considered reliable instruments for use with both clinical samples and 
the general population (Grant and Towle, 1990; Grant, 1997). The self-report measure 
that was used in this study is a reduced version of the Alcohol Use Disorder and 
Associated Disabilities Interview Schedule (AUDADIS), one of the most widely used 
diagnostic instruments of this type.  
Predictive Power and Overall Diagnostic Power Indices 
Predictive power indices (PPP and NPP) represent the probability that a disorder 
is present or absent given the results of the test. Compared to specificity and sensitivity, 
PPP is usually considered more useful to the clinician making decisions about individual 
patients (Gibertini et al, 1986; Retzlaff, 1996).   
At a 75 cut-off, the BP-MCMI-III substance dependence scales’ positive 
predictive powers (PPPs) were higher (.85 for alcohol and .83 for drug dependence) than 
those reported for the MCMI-III 1994 data set (.42 and .47) and somewhat lower than 
those reported for the 1997 data set (.88 and .93). Negative predictive power (NPP) was 
.93 for alcohol dependence and .87 for drug dependence for the BP-MCMI-III; and .96 
for both MCMI-III substance dependence scales with the 1994 sample.  At an 85 cut-off 
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the BP-MCMI-III gains more positive predictive power for both scales, but negative 
predictive powers drop below .80. 
Overall Diagnostic Power (DxP) provides a global index of a test’s overall 
classification accuracy. Generally speaking, this index is a combination of the two 
predictive power indices (PPP and NPP) and reflects the proportion of correctly classified 
subjects according to the presence or absence of a disorder. The BP-MCMI-III overall 
diagnostic power was above .80 for both substance dependence scales at the 75 and 85 
cut-offs. DxP for the original MCMI-III was not reported in the literature.  
Chance-Adjusted Indices 
Hsu (2002) argued that predictive power indices (PPP and NPP) can be 
misleading, despite the great importance they have been assigned in the literature. A 
major limitation of PPP and NPP is that, in the absence of any association between test 
scores and the presence or absence of the disorder, they can be expected to be equal to the 
prevalence of the disorder in the sample. In other words, it is only when a test shows 
predictive power indices that exceed prevalence, that one can say that diagnoses made 
based on the test are better than chance.  
Hsu (2002) demonstrated that Incremental Validity of Positive Test Diagnoses 
(IPPP) and Incremental Validity of Negative Test Diagnoses (INPP) can prevent 
misinterpretation of PPP and NPP, by proving information about how much better than 
chance a test correctly identifies positive and negative cases of a disorder. 
IPPPs obtained with the present sample for the BP-MCMI-III substance 
dependence scales were similar to those reported for the MCMI-III 1994 data set at a 75 
cut-off (.33 for the alcohol dependence and .41 for drug dependence) and somewhat 
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higher at an 85 cut-off (.40 and .47, respectively). On the other hand, compared to the 
IPPPs obtained with the MCMI-III 1997 data set (.71 and .82 for alcohol and drug 
dependence respectively), the IPPPs for the BP-MCMI-III substance dependence scales 
were much lower. 
INPPs obtained for the BP-MCMI-III at a 75 cut-off were .41 for alcohol 
dependence and .44 for drug dependence. They were somewhat lower at an 85 cut-off 
(.23 and .36 for alcohol and drug dependence, respectively), but still much higher than 
the same indices reported for both the 1994 (.08 for alcohol dependence and.04 for drug 
dependence) and 1997 (.13 for alcohol dependence and .09 for drug dependence) MCMI-
III samples.  
Unlike IPPP and INPP, which provide separate chance-adjusted measures of 
either positive or negative test diagnoses, Cohen’s Kappa can be used to measure the 
combined chance-adjusted diagnostic validities of both positive and negative test 
diagnoses (Hsu, 2002). Kappa values obtained with the present sample for the BP-
MCMI-III substance dependence scales at a 75 cut-off are .76 and .69, which are higher 
than Kappas obtained with the 1994 MCMI-III data set (.45 for alcohol dependence and 
.47 for drug dependence) and lower than Kappas obtained with the 1997 MCMI-III 
sample (.81 for alcohol dependence and .86 for drug dependence). At an 85 cut-off, 
Kappa values are somewhat lower for the BP-MCMI-III alcohol and drug dependence 
scales (.64 and .62, respectively). 
Cohen’s Effect Size and AUC 
A limitation of the use of PPP, NPP, IPPP, INPP, and Kappa as diagnostic 
validity indices is that these statistics are dependent on base rates. Cohen’s effect size, on 
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the other hand, is free from the effects of cut scores and prevalence, and can be used as a 
measure of the relative ability of a test to discriminate between groups (Hsu, 2002). 
Cohen’s effect size was 1.89 for the BP-MCMI-III alcohol dependence scale and 1.90 for 
the drug dependence scale, which are considered large (Cohen, 1988).   
The area under receiver operating characteristics curves (AUC) can also be used 
as a validity index that is free from the effects of cut scores and prevalence. According to 
Hsu (2002), this index “reflects the probability that a randomly selected person from one 
population will have a scale score that exceeds that of a randomly selected person from 
the other population.” AUC for the BP-MCMI-III substance dependence scales were both 
.94, slightly larger than the reported AUCs for the 1994 MCMI-III study and slightly 
smaller than the AUCs for the 1997 study.  
Concluding Remarks 
Diagnostic validity indices obtained with the present sample provided additional 
support for the validity of the BP-MCMI-III substance dependence scales for detecting 
alcohol- and drug-related disorders among Brazilians. Generally speaking, the diagnostic 
efficiency values obtained with this sample were approximately equal or better than those 
reported for the MCMI-III when the 1994 MCMI-III data was used for comparison; 
values were approximately equal or somewhat worse than those reported for the MCMI-
III when compared to the 1997 data set. The BP-MCMI-III diagnostic efficiency values 
obtained with the present study were consistent with the results of previous validity 
studies with the MCMI-III. Present findings suggest that the BP-MCMI-III can be a 
useful diagnostic tool.   
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Internal and External Validity of the Study 
Potential threats to internal validity (associated with group differences in terms of 
gender, marital status, education, religion, history of alcohol treatment, history of drug 
treatment and frequency of drinking) were addressed with the use of ANCOVAs during 
hypotheses testing. Although ANCOVAs can not completely remove the potential for 
selection bias with intact groups, this method is considered to be a reasonable solution for 
the problem of unequal groups if caution is exercised when interpreting the results 
(Stevens, 1990). Given the limitations of ANCOVAs for controlling the potential for 
selection bias in non-randomized studies, the conclusions about this study are presented 
tentatively. 
The fact that the sample was composed of Brazilians residing in Brazil is one of 
the strengths of this study. If data had been collected in the United States, the 
participants’ understanding of individual test items potentially would have been affected 
by acculturation, which in turn would have limited the external validity of the results.  
Nevertheless, the results of this study must be interpreted in the context of the 
characteristics of the sample it used. Participants were recruited from low-income and 
middle-income suburban areas in Rio de Janeiro, the second largest metropolitan region 
in Brazil. Although it is unlikely that Brazilians residing in other parts of Brazil would 
have responded differently to the assessment measures, it is possible that regional 
differences in the use of the Portuguese language may have affected the results.   
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Future Directions 
Findings supported the validity of the BP-MCMI-III substance dependence scales 
for detecting substance-related problems among Brazilians. Future studies should focus 
on examining the diagnostic efficiency of the scales with a sample that includes a more 
heterogeneous psychiatric population, so that new base rates can be computed. The 
validity of other BP-MCMI-III scales should also be examined so that the instrument’s 
overall diagnostic utility can be ascertained.     
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A Brazilian-Portuguese version of the MCMI-III was developed to be 
used in future studies that will examine cross-cultural aspects of 
personality and psychopathology in Brazil and the United States. This 
paper presents the translation methodology for this endeavor and the 
preliminary statistical results. The linguistic equivalency of the two 
versions was evaluated with a group of bilingual individuals in the 
United States. Item-by-item agreement rates ranged from 44% to 
100% (Median=90.4%). The median correlation between English and 
Brazilian-Portuguese versions across the 27 scales was .83 (range = 
.07 to .96). These results are seen as encouraging and suggest 
consistency of measurement across cultures. 
 
 
The Millon Clinical Multiaxial 
Inventory (MCMI) is currently one of the 
most popular instruments used for the 
assessment of adult psychopathology in the 
United States (Choca & Van Denburg, 
1997). It has inspired a growing number of 
studies since its first publication in 1977 and 
now, in its third version, occupies a central 
place in many clinical settings (Craig, 1997). 
Several translations and adaptations of the 
Millon Inventories to other languages have 
been reported in the literature and are 
currently being used in many other countries 
(e.g. Sloore & Derksen, 1997; Mortensen & 
Simonsen, 1990; Luteijn, 1990). 
According to Escovar (1997), the 
MCMI is particularly appropriate for cross-
cultural applications. Because of its solid 
theoretical foundation, the MCMI allows for 
the assessment of personality disorders and 
clinical syndromes at a basic, theoretical 
level. Moreover, the MCMI’s consonance 
with the DSM-IV allows for the 
interpretation and reporting of results 
according to the current psychiatric 
nosology used in many countries (Millon & 
Millon, 1997). 
Due to the demand for psychological 
instruments that can be appropriately used 
with Portuguese speaking individuals of 
Brazilian heritage, we conducted a 
translation of the MCMI-III into Brazilian-
Portuguese. Only a small number of 
instruments are now available for clinical 
and research purposes with a Brazilian 
population and a good part of these 
instruments are based on projective 
diagnostic approaches. There is a need for 
self-report measures in Brazilian-Portuguese 
that are reliable, easy to use in a variety of 
clinical settings, and up-to-date with the 
most current theories of personality and 
psychopathology. 
The current literature provides several 
guidelines for the translation and adaptation 
of psychological instruments for cross-
cultural use (see Van de Vijver & 
Hambleton, 1996, for a comprehensive 
description of potential sources of bias and 
recommended practices). The 
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translation/back translation procedure is 
considered standard by most test translators 
and is used to evaluate whether original item 
content is preserved or changed in the 
translated version. In this procedure, the 
translated items are translated back into the 
source language and then compared with the 
original version of the instrument to check 
for content discrepancies. Although this 
method seems to be a common procedure 
among test translators (e.g. Sloore & 
Derksen 1997; Saito, Nomura, Noguchi & 
Tezuka, 1996), the literature advises that it 
should be used with caution. According to 
Geisinger (1994), research has found that 
test translators, when knowing that their 
work will be subject to back translation, tend 
to use wording that ensures a good match 
between back translation and original 
version, rather than one that accurately 
reproduces the original content of the items. 
Moreover, readability and fluency of the text 
tend to be neglected when back translation 
procedures are employed (Van de Vijver & 
Hambleton, 1996). Other authorities in the 
field have concluded, however, that back 
translation is a valuable tool despite its 
limitations and should be implemented by 
test translators (Butcher, 1996). 
As an alternative technique to back 
translation, the use of revisers has been 
suggested by Geisinger (1994). He 
recommended having a group of individuals 
carefully review all translated items, make 
comments about the quality of the 
translation, and discuss with test translators 
alternative wording for problem-items. This 
review process is also expected to minimize 
the potential for translation bias as well as to 
enhance the quality of the final product. 
 Another recommended practice is the 
use of a committee approach to translation 
(Butcher, 1998; Sloore & Derksen 1997; 
Saito et al, 1996; Butcher, 1996). Rather 
than having only one person translate the 
instrument, the literature suggests having 
members of a translation team make the 
translation of all items independently and 
later integrate their work into one version on 
the basis of discussion. The committee 
members should be not only fluent in both 
languages but also knowledgeable about 
both cultures and the constructs being 
measured (Geisinger, 1994). 
Finally, in order to further evaluate 
the linguistic accuracy of a translated 
instrument, a pilot study using bilingual 
individuals should be carried out (Butcher, 
1998; Sloore & Derksen, 1997; Butcher, 
1996; Saito et al., 1996). In this method, 
both versions are administered to a sample 
of bilingual subjects to detect problems with 
particular items and evaluate the reliability 
of the instrument across versions. Frequent 
discrepancies between same items are 
expected to indicate possible translation 
problems and would suggest the need for 
further refinement of the translated item. 
The correlation coefficients obtained are 
expected to approximate the test-retest 
reliability coefficients reported in the 
literature for the original version of the 
instrument. 
The purpose of the present paper is to 
describe the methodology used for the 
translation of the MCMI-III into Brazilian-
Portuguese and to present the bilingual pilot 
results. As noted above, correlations are 
expected to approximate the test-retest 
reliability of the MCMI-III. Further studies 
will be required to evaluate the 
psychometric properties of the new 
instrument (Paunonen & Ashton, 1998) and 
its validity for use with a Brazilian 
population. Validity-threatening factors 
related to the construct being measured 
(construct bias) and to instrument 
administration (method bias) should also be 
examined in the future to ensure appropriate 
clinical and research use (Van de Vijver & 
Hambleton, 1996).  
Method 
Translation Procedures 
Our research team reviewed the 
translation practices recommended in the 
literature (Butcher, 1998; Butcher, 1996; 
Van de Vijver & Hambleton, 1996; 
Geisinger, 1994) and considered the 
expertise of others who have translated tests 
(e.g., Sloore & Derksen, 1997; Saito et al, 
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1996) before initiating the translation of the 
MCMI-III into Brazilian- Portuguese. A 
combination of the practices discussed in the 
introduction was deemed appropriate for our 
study. 
Initial Translation and Revision 
A committee approach was used in 
which the initial translation was conducted 
independently by each member of the 
committee and then integrated on the basis 
of discussion. This committee consisted of 
two bilingual Brazilians with cross-cultural 
experience (two of the authors). Both had 
more than 10 years of clinical experience 
and were familiar with the content of the 
MCMI-III. 
The initial translation was then revised 
by two research assistants who were selected 
to participate in this project due to their 
extensive experience in both cultures and 
their knowledge of English and Brazilian-
Portuguese grammar. One reviser was an 
American who had spent more than 15 years 
working in Brazil and fully comprehended 
the nuances of both languages. The second 
reviser was a Brazilian who had been 
studying and working in the United States 
for 8 years (she currently works as a mental 
health counselor and professional translator 
in Broward County, Florida, USA). Because 
the revisers were not familiar with the 
content of the MCMI-III, their suggestions 
were analyzed by the translation committee 
who made the necessary adjustments to the 
items before submitting them to the back 
translation procedure. 
When working on the items 
independently, the translation committee 
and the revisers were instructed to keep 
several principles in mind: (1) if possible, 
maintain the original wording and sentence 
construction; (2) if necessary, modify the 
wording and/or sentence construction 
making changes as minimal as possible; (3) 
try to use words and sentences that are easy 
to understand; (4) if there is more than one 
way an item can be translated, choose the 
most simple one; (5) if necessary, use 
explanatory words/sentences within 
parenthesis to clarify words that have 
ambiguous meaning. 
Back Translation 
Back translation was conducted by 
another Brazilian research assistant with 
extensive experience in both cultures (more 
than 20 years working in the United States). 
The back translated items were latter 
compared to the original items by an 
American research assistant who had no 
knowledge of Portuguese. When 
discrepancies were found between back 
translated items and their correspondent 
items in the original version, the translation 
committee and the back translator worked 
together to detect the reason for the 
problems, generate alternative formulations, 
and prepare the final version used in the 
bilingual retest study. 
Bilingual Retest Strategy 
Participants 
Potential subjects were recruited from 
the community on the basis of their 
availability. They were contacted informally 
through schools, churches, and businesses 
that serve the Brazilian community in Dade 
and Broward Counties (Florida, USA). They 
were informally approached by the 
investigators and invited to participate in the 
study by responding anonymously to the 
assessment materials. At this time they 
received a brief explanation of the purpose 
of the study and were assured of their 
anonymity. Those who volunteered were 
scheduled for a first interview with one of 
the researchers.  
During this first interview all 
volunteers were fully informed about risks 
and benefits associated with their 
participation, their right to withdraw from 
the study at any time, and the procedures 
involved, including those related to ensuring 
their anonymity. Those who agreed to 
participate were asked to sign an Informed 
Consent Form. All subjects were treated in 
accordance with the ethical guidelines of the 
American Psychological Association. 
Criteria for inclusion in this study were: 
(1) subject’s willingness to participate; (2) 
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above 18 years of age; (3) above 8 years of  
education; and (4) ability to speak and read 
English and Brazilian-Portuguese. Subjects 
were excluded from the study if they scored 
below the 8th Grade level on the reading 
subtest of  the Wide Range Achievement 
Test - 3rd Ed. (WRAT-III; Wilkinson, 
1993).  
A total number of twenty-one 
Brazilian individuals fluent in Brazilian-
Portuguese and English volunteered for this 
study. From this group, four volunteers 
failed to appear for the second interview, 
two did not meet criteria for inclusion in the 
study, and six were not able to complete 
retest in time to be included in this report. 
The remaining participants were 5 males and 
4 females with ages ranging from 34 to 58 
(Mean = 41.7) and years of education 
ranging from 10 to 22 (Mean = 12.7). 
Instrumentation 
Millon Clinical Multiaxial Inventory - 
III. The MCMI-III (Millon, 1994) is a 175-
item instrument composed of 11 clinical 
personality scales, 3 severe personality 
pathology scales, 7 clinical syndrome scales, 
3 severe syndrome scales, and 4 modifying 
indices scales. Due to the norming of the 
MCMI-III on psychiatric patients, base rates 
(BR) are employed rather than standard 
scores. A BR score of > 75 on a given scale 
indicates that feature is present in the 
individual's personality, while a BR score of 
> 85 indicates that feature is prominent in 
the composition of their personality. 
Strengths of the MCMI-III include its 
norming on a psychiatric population, its 
brevity, and its ease of administration. 
Moreover, the Millon inventories appeal to 
many professionals as they define 
personality traits using nomenclature with 
which clinicians are accustomed (Choca & 
Van Denburg, 1997; McCabe, 1984). 
According to Millon (1994), internal 
consistency (alpha) coefficients exceed .80 
for 20 of the 26 scales. Also, the median 
stability coefficient, based on two test 
administrations between five and 14 days 
apart, was .91. Regarding validity, Millon 
reported that correlations between scale BR 
scores and collateral instruments (e.g., BDI, 
MMPI-2, SCL-90-R) were generally 
favorable.  
Wide Range Achievement Test - III. 
The WRAT-III has one level for ages 5-75. 
There are three forms (blue, tan, and 
combined). The total number of possible 
points for each of the alternate forms (blue, 
tan) is 57, and 99 for the combined form. 
Like the WRAT-R, it has good 
psychometric properties (Wilkinson, 1993). 
Reliability, as measured by a coefficient 
Alpha, ranges from .85 to .95 over the 3 
forms; test-retest reliability is .91 to .98. 
Correlations for the alternate forms over the 
age groups range from .87 to .99, with a 
median correlation of .92. The WRAT-III 
has three subtests (Reading, Spelling, and 
Arithmetic). Correlations between the 
WRAT-III and WRAT-R reading tests based 
on studies with children are: blue form (.90), 
tan form (.95), and combined form (.94). 
Procedure 
Participants were randomly assigned to 
two conditions to control for possible order 
effects. Participants in one condition were 
tested on the English version of the MCMI-
III during the first interview and on the 
Portuguese version of the MCMI-III after an 
interval of 6-14 days, on the second 
interview. Participants in the other condition 
took the English and Portuguese versions of 
the MCMI-III in an inverse order.  
Participants in both conditions took the 
Reading subtest of the WRAT-III (tan form) 
during the second interview. The Reading 
subtest of the WRAT-III was used for 
subject screening and was administered only 
after the subjects had completed the two 
versions of the MCMI-III to prevent subjects 
who did not qualify for the study from 
feeling inadequate about their knowledge of 
English. 
Data collection took place in different 
community locations (homes, churches, or 
business sites) to accommodate the subjects’ 
preferences. It was considered the 
researchers’ responsibility (or other 
qualified test administrator selected by the 
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researchers), however, to ensure that testing 
conditions were optimal before 
administering the tests. 
 
Results 
We found an average item-by-item 
agreement of 90.5% (ranging from 44.4% to 
100% agreement).  Of the 175 items, 78 
achieved 100% agreement, while only 2 
items failed to achieve at least a 60% 
agreement rate (item 88 with 44.4% and 
item 32 with 55.6%). Agreement rates for all 
items are presented on Table 1. 
Test-retest correlations for BR scores 
for all scales were also calculated and are 
presented on Table 2 along with first, second 
& difference means and standard deviations 
and Cohen's d statistic. The median 
correlation between versions was .83 (range 
= .07 to .96). The d values ranged from 0 to 
.6 (Median=.3). 
Discussion 
The present paper outlined the 
methodology used for the translation of the 
MCMI-III into Brazilian-Portuguese and 
presented the results of the bilingual retest 
study. The results are encouraging and may 
suggest consistent measurement across 
cultures and linguistic equivalency between 
the original and the translated instrument. 
We are aware, however, that a linguistically 
equivalent translation does not necessarily 
indicate that both versions are comparable in 
all aspects that are important to ensure 
appropriate clinical and research use. 
Further studies to evaluate the psychometric 
properties of the translated instrument and 
its validity for use with Brazilians are now 
being conducted by our research team and 
represent the preliminary steps we have 
taken to provide method for future cross-
cultural studies of personality using the 
translated Millon.  
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Table 1 
Item by Item Agreement Rates Between Testings 
 
  
 Pct.           Pct.           Pct.         Pct.           Pct.           Pct.           Pct. 
Item Agree Item Agree Item Agree Item Agree Item Agree Item Agree Item Agree 
 
 
 001    100.0 026       88.9    051       77.8    076       88.9    101       77.8    126       88.9    151   88.9 
 002       77.8    027       77.8    052    100.0    077    100.0    102    100.0    127       66.7    152    100.0 
 003    100.0    028       88.9    053       66.7    078    100.0    103    100.0    128    100.0    153       88.9 
 004    100.0    029    100.0    054       88.9    079       66.7    104       77.8    129   100.0    154    100.0 
 005    100.0    030    100.0    055       88.9    080       88.9    105       66.7    130       88.9    155        88.9 
 006       88.9    031    100.0    056       88.9    081    100.0    106       77.8    131       88.9    156    100.0 
 007       66.7    032       55.6    057       66.7    082       88.9    107    100.0    132    100.0    157    100.0 
 008    100.0    033       88.9    058       88.9    083       77.8    108       88.9    133       88.9    158    100.0 
 009       88.9    034       88.9    059       66.7    084       77.8    109    100.0    134       88.9    159    100.0 
 010    100.0    035       77.8    060       88.9    085       88.9    110    100.0    135       66.7    160    100.0 
 011    100.0    036       88.9    061       88.9    086    100.0    111    100.0    136       88.9    161       88.9 
 012    100.0    037    100.0    062       88.9    087    100.0    112    100.0    137       66.7    162       88.9 
 013    100.0    038    100.0    063       88.9    088       44.4    113    100.0    138       88.9    163    100.0 
 014       88.9    039    100.0    064    100.0    089    100.0    114    100.0    139    100.0    164    100.0 
 015    100.0    040       77.8    065    100.0    090       88.9    115       88.9    140       88.9    165       88.9 
 016       77.8    041       77.8    066    100.0    091    100.0    116       77.8    141    100.0    166       77.8 
 017    100.0    042    100.0    067    100.0    092       88.9    117       88.9    142       88.9    167       77.8 
 018    100.0    043       88.9    068       88.9    093       77.8    118    100.0    143    100.0    168    100.0 
 019       88.9    044    100.0    069    100.0    094       88.9    119    100.0    144       88.9    169    100.0 
 020       88.9    045       66.7    070       88.9    095    100.0    120    100.0    145       88.9    170       66.7 
 021    100.0    046    100.0    071       88.9    096       77.8    121       88.9    146    100.0    171    100.0 
 022       88.9    047       77.8    072       88.9    097       88.9    122       88.9    147       88.9    172       66.7 
 023       88.9    048       88.9    073    100.0    098       88.9    123    100.0    148       77.8    173    100.0 
 024    100.0    049       88.9    074    100.0    099       77.8    124       88.9    149    100.0    174    100.0 
 025    100.0    050       66.7    075       88.9    100    100.0    125    100.0    150       88.9    175    100.0 
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Table 2 
First vs. Second Testing Statistics 
------------------------------------------------------------------------------------------------------------------------------------------- 
                1st Test     2nd Test              Difference 
                ----------   ----------             ---------- 
Scale                   Mean   SD    Mean   SD     r        Mean   SD      d 
------------------------------------------------------------------------------------------------------------------------------------------- 
1  Schizoid             52.9  18.8   53.7  18.3   .65       -0.8  15.5   -0.0 
2A Avoidant             24.1  20.5   38.0  31.5   .90**    -13.9  15.7   -0.5 
2B Depressive           24.4  26.5   33.1  35.3   .79*      -8.7  21.5   -0.3 
3  Dependent            32.6  30.5   40.2  30.0   .75*      -7.7  21.2   -0.3 
4  Histrionic           62.3  13.1   59.8  18.3   .78*       2.6  11.5    0.2 
5  Narcissistic         69.8  14.4   65.8  16.7   .93**      4.0   6.2    0.3 
6A Antisocial           41.8  27.9   48.6  20.6   .55       -6.8  23.7   -0.3 
6B Aggressive/Sadistic  40.3  25.4   46.0  19.7   .83**     -5.7  14.3   -0.2 
7  Compulsive           64.2  16.5   58.2  10.4   .79*       6.0  10.5    0.4 
8A Passive-Aggressive   28.2  16.8   39.2  21.5   .94**    -11.0   8.0   -0.6 
8B Self-Defeating       18.6  21.8   30.3  33.3   .92**    -11.8  15.6   -0.4 
S  Schizotypal          21.4  27.2   29.2  34.8   .96**     -7.8  11.7   -0.2 
C  Borderline           17.1  19.7   28.3  23.3   .68*     -11.2  17.6   -0.5 
P  Paranoid             26.0  28.9   23.3  26.3   .93**      2.7  10.5    0.1 
A  Anxiety              24.1  32.9   35.9  41.2   .86**    -11.8  21.1   -0.3 
H  Somatoform           16.9  26.9   17.7  28.4   .85**     -0.8  15.2   -0.0 
N  Bipolar: Manic       30.0  31.3   30.7  34.6   .94**     -0.7  11.4   -0.0 
D  Dysthymia             8.9  20.3   18.7  25.2  -.07       -9.8  33.5   -0.4 
B  Alcohol Dependence   49.6  19.0   53.7  18.3   .86**     -4.1   9.8   -0.2 
T  Drug Dependence      40.1  23.5   47.6  23.6   .57       -7.4  21.8   -0.3 
R  PTSD                  8.3  10.9   18.3  23.5   .76*     -10.0  16.8   -0.5 
SS Thought Disorder     16.9  19.0   17.8  26.5   .89**     -0.9  12.7   -0.0 
CC Major Depression      9.8  20.0   18.2  28.1   .76*      -8.4  18.2   -0.3 
PP Delusional Disorder  19.4  26.6   27.9  33.1   .85**     -8.4  17.3   -0.3 
Y  Desirability         77.8  14.2   70.3  10.8   .76*       7.4   9.3    0.6 
Z  Debasement           22.7  22.0   23.1  28.3   .61       -0.4  23.0   -0.0 
X  Disclosure           37.8  20.3   43.9  19.1   .92**     -6.1   7.7   -0.3 
------------------------------------------------------------------------------------------------------------------------------------------ 
** p<.01  *p<.05                              
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A Brazilian-Portuguese version of the MCMI-III was developed to be 
used in future studies that will examine cross-cultural aspects of 
personality and psychopathology in Brazil and the United States. This 
paper presents the methodology used to evaluate the translation 
methodology for this endeavor (with its statistical results) and test-
retest reliability of the translated instrument. For evaluation of the 
translation phase, using 9 bilingual participants, we found item-by-item 
agreement rates ranged from 44% to 100% (Median=90.4%) between 
English and Brazilian-Portuguese versions. The median correlation 
across the 27 scales was .83 (range = .07 to .96).  For the test-retest 
phase, using 222 Brazilian college students, the median raw score 
correlation between first and second testing across the 27 scales was 
.82 (range = .48 to .86). These results are seen as encouraging and 
suggest consistency of measurement across time. 
 
  The Millon Clinical Multiaxial Inventory 
(MCMI) is currently one of the most popular 
instruments used for the assessment of adult 
psychopathology in the United States (Choca 
& Van Denburg, 1997). It has inspired a 
growing number of studies since its first 
publication in 1977 and now, in its third 
version, occupies a central place in many 
clinical settings (Craig, 1997). Several 
translations and adaptations of the Millon 
Inventories to other languages have been 
reported in the literature and are currently 
being used in many other countries (e.g. 
Sloore & Derksen, 1997; Mortensen & 
Simonsen, 1990; Luteijn, 1990). 
  Because of its solid theoretical 
foundation, the MCMI seems particularly 
appropriate for cross-cultural applications 
(Escovar, 1997), allowing for the assessment 
of personality disorders and clinical 
syndromes at a basic, theoretical level. 
Moreover, the instrument’s consonance with 
the DSM-IV and ICD-10 facilitates the 
interpretation and reporting of results 
according to the current psychiatric nosology 
used in many countries (Millon & Millon, 
1997). 
  Due to the demand for 
psychological instruments that can be 
appropriately used with Portuguese speaking 
individuals of Brazilian heritage, we 
conducted a translation of the MCMI-III into 
Brazilian-Portuguese. Only a small number 
of instruments are now available for clinical 
and research purposes with a Brazilian 
population and a good part of these 
instruments are based on projective 
diagnostic approaches. There is a need for 
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self-report measures in Brazilian-Portuguese 
that are reliable, easy to use in a variety of 
clinical settings, and up-to-date with the 
most current theories of personality and 
psychopathology. 
  The current literature provides several 
guidelines for the translation and adaptation 
of psychological instruments for cross-
cultural use (see Van de Vijver & Hambleton, 
1996, for a comprehensive description of 
potential sources of bias and recommended 
practices). The translation/back translation 
procedure is considered standard by most test 
translators and is used to evaluate whether 
original item content is preserved or changed 
in the translated version. In this procedure, the 
translated items are translated back into the 
source language and then compared with the 
original version of the instrument to check for 
content discrepancies. Although this method 
seems to be a common procedure among test 
translators (e.g. Sloore & Derksen 1997; 
Saito, Nomura, Noguchi & Tezuka, 1996), the 
literature advises that it should be used with 
caution. According to Geisinger (1994), 
research has found that test translators, when 
knowing that their work will be subject to 
back translation, tend to use wording that 
ensures a good match between back 
translation and original version, rather than 
one that accurately reproduces the original 
content of the items. Moreover, readability 
and fluency of the text tend to be neglected 
when back translation procedures are 
employed (Van de Vijver & Hambleton, 
1996). Other authorities in the field have 
concluded, however, that back translation is a 
valuable tool despite its limitations and should 
be employed by test translators (Butcher, 
1996). 
  As an alternative technique to back 
translation, the use of revisers has been 
suggested by Geisinger (1994). He 
recommended having a group of individuals 
carefully review all translated items, make 
comments about the quality of the translation, 
and discuss with test translators alternative 
wording for problem-items. This review 
process is also expected to minimize the 
potential for translation bias as well as to 
enhance the quality of the final product. 
  Another recommended practice is the use 
of a committee approach to translation 
(Butcher, 1998; Sloore & Derksen 1997; Saito 
et al, 1996; Butcher, 1996). Rather than 
having only one person translate the 
instrument, the literature suggests having 
members of a translation team make the 
translation of all items independently and later 
integrate their work into one version on the 
basis of discussion. The committee members 
should be not only fluent in both languages 
but also knowledgeable about both cultures 
and the constructs being measured (Geisinger, 
1994). 
  Furthermore, in order to evaluate the 
linguistic accuracy of a translated instrument, 
a pilot study using bilingual individuals 
should be carried out (Butcher, 1998; Sloore 
& Derksen, 1997; Butcher, 1996; Saito et al., 
1996). In this method, both versions are 
administered to a sample of bilingual subjects 
to detect problems with particular items and 
evaluate the reliability of the instrument 
across versions. Frequent discrepancies 
between same items are expected to indicate 
possible translation problems and would 
suggest the need for further refinement of the 
translated item. Genuine cultural differences 
that may account for these discrepancies 
should be also investigated (Butcher, 1996).  
  Finally, the stability of the translated 
instrument should be tested in the target 
culture with a test-retest design (Paunonen & 
Ashton, 1998). The correlation coefficients 
obtained are expected to approximate the test-
retest reliability coefficients reported in the 
literature for the original version of the 
instrument.  
  The purpose of the present paper is to 
describe the methodology used for the 
translation of the MCMI-III into Brazilian-
Portuguese and to present the preliminary 
psychometric results obtained with a sample 
of Brazilian college students in Rio de Janeiro 
and Sao Paulo (Brazil). As noted above, 
correlations are expected to approximate the 
test-retest reliability of the original MCMI-III 
reported in the manual (Millon, 1994). Further 
studies will be required to evaluate the 
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validity of the new instrument for use with a 
Brazilian population. Validity-threatening 
factors related to the construct being 
measured (construct bias) and to instrument 
administration (method bias) should be 
examined in the future to ensure appropriate 
clinical and research use (Van de Vijver & 
Hambleton, 1996). 
Method 
Translation Procedures 
  Our research team used a combination 
of the translation practices discussed in the 
literature (Butcher, 1998; Sloore & Derksen, 
1997; Saito et al, 1996; Butcher, 1996; Van 
de Vijver & Hambleton, 1996; Geisinger, 
1994). The initial translation was conducted 
independently by two bilingual Brazilians 
(two of the authors) and integrated on the 
basis of discussion. The integrated version 
was then revised by two bilingual research 
assistants with extensive experience in both 
cultures who made important comments and 
suggestions regarding each item. However, 
because the revisers were not familiar with the 
content of the MCMI-III, their suggestions were 
analyzed by the translation committee who made 
the necessary adjustments to the items before 
submitting them to the back translation 
procedure. 
  When working on the items 
independently, the translation committee and 
the revisers were instructed to keep several 
principles in mind: (1) if possible, maintain 
the original wording and sentence 
construction; (2) if necessary, modify the 
wording and/or sentence construction making 
changes as minimal as possible; (3) try to use 
words and sentences that are easy to 
understand; (4) if there is more than one way 
an item can be translated, choose the most 
simple one; (5) if necessary, use explanatory 
words/sentences within parenthesis to clarify 
words that have ambiguous meaning. 
  Back translation was conducted by 
another Brazilian research assistant with 
extensive experience in both cultures. The 
back translated items were latter compared to 
the original items by an American research 
assistant who had no knowledge of 
Portuguese. When discrepancies were found 
between back translated items and their 
correspondent items in the original version, 
the translation committee and the back 
translator worked together to detect the reason 
for the problems, generate alternative 
formulations, and prepare the version used in 
the bilingual retest study. 
 
Bilingual Retest 
Participants 
  Potential subjects were recruited from the 
community on the basis of their availability. 
They were contacted informally through 
schools, churches, and businesses that serve 
the Brazilian community in Dade and 
Broward Counties (Florida, USA). They were 
informally approached by the investigators 
and invited to participate in the study by 
responding anonymously to the assessment 
materials. At this time they received a brief 
explanation of the purpose of the study and 
were assured of their anonymity.  
  Criteria for inclusion in this study were: 
(1) subject’s willingness to participate; (2) 
above 18 years of age; (3) above 8 years of 
education; and (4) ability to speak and read 
English and Brazilian-Portuguese. Subjects 
were excluded from the study if they scored 
below the 8th Grade level on the reading 
subtest of the Wide Range Achievement Test 
- 3rd Ed. (WRAT-III; Wilkinson, 1993).  
  A total number of twenty-one Brazilian 
individuals fluent in Brazilian-Portuguese and 
English volunteered for this study. From this 
group, ten volunteers failed to appear for the 
second interview and two did not meet criteria 
for inclusion in the study. The remaining 
participants were 5 males and 4 females with 
ages ranging from 34 to 58 (Mean = 41.7) and 
years of education ranging from 10 to 22 
(Mean = 12.7). 
Instrumentation 
  Millon Clinical Multiaxial Inventory - 
III. The MCMI-III (Millon, 1994) is a 175-
item instrument composed of 11 clinical 
personality scales, 3 severe personality 
pathology scales, 7 clinical syndrome scales, 
3 severe syndrome scales, and 4 modifying 
indices scales. Due to the norming of the 
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MCMI-III on psychiatric patients, base rates 
(BR) are employed rather than standard 
scores. A BR score of > 75 on a given scale 
indicates that feature is present in the 
individual's personality, while a BR score of > 
85 indicates that feature is prominent in the 
composition of their personality. Strengths of 
the MCMI-III include its norming on a 
psychiatric population, its brevity, and its ease 
of administration. Moreover, the Millon 
inventories appeal to many professionals as 
they define personality traits using 
nomenclature with which clinicians are 
accustomed (Choca & Van Denburg, 1997; 
McCabe, 1984). According to Millon (1994), 
internal consistency (alpha) coefficients 
exceed .80 for 20 of the 26 scales. Also, the 
median stability coefficient, based on two test 
administrations between five and 14 days 
apart, was .91. Regarding validity, Millon 
reported that correlations between scale BR 
scores and collateral instruments (e.g., BDI, 
MMPI-2, SCL-90-R) were generally 
favorable.  
   
  Wide Range Achievement Test - III. The 
WRAT-III has one level for ages 5-75. There 
are three forms (blue, tan, and combined). The 
total number of possible points for each of the 
alternate forms (blue, tan) is 57, and 99 for the 
combined form. Like the WRAT-R, it has 
good psychometric properties (Wilkinson, 
1993). Reliability, as measured by a 
coefficient Alpha, ranges from .85 to .95 over 
the 3 forms; test-retest reliability is .91 to .98. 
Correlations for the alternate forms over the 
age groups range from .87 to .99, with a 
median correlation of .92. The WRAT-III has 
three subtests (Reading, Spelling, and 
Arithmetic). Correlations between the 
WRAT-III and WRAT-R reading tests based 
on studies with children are: blue form (.90), 
tan form (.95), and combined form (.94). 
Procedure 
  Participants were randomly assigned to 
two conditions to control for possible order 
effects. Participants in one condition were 
tested on the English version of the MCMI-III 
during the first interview and on the 
Portuguese version of the MCMI-III after an 
interval of 6-14 days, on the second interview. 
Participants in the other condition took the 
English and Portuguese versions of the 
MCMI-III in an inverse order.  
  Participants in both conditions took the 
Reading subtest of the WRAT-III (tan form) 
during the second interview. The Reading 
subtest of the WRAT-III was used for subject 
screening and was administered only after the 
subjects had completed the two versions of 
the MCMI-III to prevent subjects who did not 
qualify for the study from feeling inadequate 
about their knowledge of English. 
  Data collection took place in different 
community locations (homes, churches, or 
business sites) to accommodate the subjects’ 
preferences. It was considered the 
researchers’ responsibility (or other qualified 
test administrator selected by the researchers), 
however, to ensure that testing conditions 
were optimal before administering the tests. 
Results 
  We found an average item-by-item 
agreement of 90.5% (ranging from 44.4% to 
100% agreement).  Of the 175 items, 78 
achieved 100% agreement, while only 2 items 
failed to achieve at least a 60% agreement rate 
(item 88 with 44.4% and item 32 with 
55.6%). Test-retest correlations for BR scores 
for all scales were also calculated (median 
correlation = .83; range = .07 to .96). The d 
values ranged from 0 to .6 (Median=.3).  
  These results were seen as encouraging 
and suggestive of consistent measurement 
across cultures. Items with lower than 80% 
agreement were subsequently revised by the 
translation committee who worked together to 
detect the reason for the problems and to 
generate alternative formulations before 
preparing the final version used in the retest 
study in Brazil. Because the subjects reported 
having difficulty understanding certain items 
in the English version during test 
administration, their limited comprehension 
of English was also considered as a possible 
explanation for the low agreement achieved 
with particular items.  
Test-Retest in Brazil 
Participants 
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 A total of two hundred and thirty 
five Brazilian College students residing in 
Rio de Janeiro and Sao Paulo (Brazil) were 
recruited for this study. They were contacted 
during class hours by a member of our 
research team and invited to participate by 
responding anonymously to the assessment 
materials. One point toward the final grade 
was offered as an incentive for participation.  
 The subjects were fully informed 
about the procedures involved, the risks and 
benefits associated with their participation, 
and their right to withdraw from the study at 
any time. Confidentiality was assured and 
those who agreed to participate were asked to 
sign an Informed Consent Form. The criteria 
for inclusion in this study were: (1) subject’s 
willingness to participate; and (2) above 18 
years of age.   
 Only a subset of the total data (n=45) 
was analyzed in time to be included in this 
report. The sub-sample consisted of 44 female 
and 1 male students with an average of 25.7 
years of age (SD=8.3) and 15.5 years 
(SD=3.2) of education.  
Procedure 
 Each participant was twice 
administered the Brazilian-Portuguese 
translation of the third edition of the Millon 
Clinical Multiaxial Inventory (MCMI3-BP) 
during class hours. The interval between the 
first and second administrations varied 
somewhat but was about two weeks on 
average (Mean=13 days, SD=2.2). 
Information regarding the participants’ past 
and current psychiatric history, as well as 
substance use and trauma, were also collected 
and will be presented in future reports. 
Results 
 Stability coefficients were computed 
by calculating the Pearson correlations 
between scores produced at the first and 
second testings. These are shown in Table 1 
for both the raw scores and the base rate (BR) 
scores. The median correlation between first 
and second testing across the 27 scales was 
.82 (range = .41 to .92) for raw scores and .79 
(range=.49 to .87) for base rates. These results 
are seen as encouraging and suggest 
consistency of measurement across time. 
Discussion 
 The present paper outlined the 
methodology used for the translation of the 
MCMI-III into Brazilian-Portuguese and 
presented the preliminary psychometric 
results obtained with a sample of Brazilian 
college students. These results are 
encouraging and suggest that the translated 
instrument is reliable and comparable to the 
original MCMI-III. Correlations for all but 
the substance abuse scales were above .6 
and significant at .001 level. Since the 
participants in this study were students, it’s 
not surprising that there would be some 
inconsistency in their responses to items 
measuring alcohol and drug dependence. 
 We are aware, however, that a 
psychometrically equivalent translation does 
not necessarily indicate that both versions are 
comparable in all aspects that are important to 
ensure appropriate clinical and research use. 
Further studies to evaluate its validity for use 
with Brazilians are now being conducted by 
our research team and represent the 
preliminary steps we have taken to provide 
method for future cross-cultural studies of 
personality using the translated Millon.  
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Table 1 
Stability Coefficients for 
BP-MCMI-III Raw and BR Scores 
 
Scale            Raw        BR    
 
1  Schizoid           .781**   .791** 
2A Avoidant           .864**   .867** 
2B Depressive         .925**   .864** 
3  Dependent          .851**   .833** 
4  Histrionic         .698**   .786** 
5  Narcissistic       .733**   .730** 
6A Antisocial         .731**   .765** 
6B Aggress/Sadistic   .756**   .784** 
7  Compulsive         .829**   .845** 
8A Passive/Aggressive .776**   .747** 
8B Self-Defeating     .875**   .795** 
S  Schizotypal        .804**   .647** 
C  Borderline         .869**   .864** 
P  Paranoid           .830**   .784** 
A  Anxiety            .705**   .682** 
H  Somatoform         .868**   .819** 
N  Bipolar: Manic     .817**   .836** 
D  Dysthymia          .781**   .752** 
B  Alcohol Dep        .697**   .576** 
T  Drug Dep           .849**   .572*   
R  PTSD               .819**   .732** 
SS Thought D/O        .797**   .803** 
CC Major Depression   .878**   .863** 
PP Delusional D/O     .789**   .775** 
Y  Desirability       .729**   .713** 
Z  Debasement         .869**   .820** 
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X  Disclosure         .860**   .855** * p<.01      ** p<.001     
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APPENDIX C 
 
Informed Consent (English Version) 
Validity of the Substance Abuse Scales of the Brazilian-Portuguese MCMI-III 
 
Primary Investigator:    
    Cristina Magalhães, M.S., L.M.H.C. 
    251 NE 38th ST #309 
    Oakland Park, FL 33334 
    Phone: (954) 568-1106 
    E-mail: magalhac@nova.edu 
 
Faculty Research Advisors: 
    Alfred Sellers, Ph.D.
    3301 College Avenue 
    Fort Lauderdale, FL 33314 USA 
    Phone: (954) 262-5810 
    E-mail: sellers@nova.edu 
 
Research Associate: 
    Monica Schaly, M.S., L.M.H.C. 
    Telephone: 011 55 (021) 3393-2687 
    E-Mail: billynile@yahoo.com.br 
 
 
    Linda Sobell, Ph.D. 
    3301 College Avenue 
    Fort Lauderdale, FL 33314 USA 
    Phone: (954) 262-5811 
    E-mail: sobelll@nova.edu  
 
Institutional Review Board: 
    IRB approval #: CPS07060401X 
    Date of Approval: 07/15/04 
    Funding Source: None 
    Phone Number: (954) 262-5369 
 
    John Lewis, Ph.D. 
    3301 College Avenue 
    Fort Lauderdale, FL 33314 USA 
    Phone: (954) 262-5729 
    E-mail: lewis@nova.edu 
 
I. Description of the Study: 
 
I understand that Cristina Magalhães is a doctoral student at Nova Southeastern University engaged in 
research for the purpose of fulfilling a requirement for the Doctor of Psychology Degree. I further 
understand that this research seeks to evaluate the validity of the Brazilian-Portuguese version of the Millon 
Clinical Multiaxial Inventory-III (MCMI-III) for assessing substance abuse problems in the Brazilian 
population.  
 
The MCMI-III is a psychological test that was designed to measure personality traits and clinical 
syndromes in individuals with different types of problems, including substance abuse. This test was 
originally developed in the English language and has been considered valid for use with people who live in 
the United States. The researchers are interested in evaluating whether it can be useful for assessing 
substance abuse problems among Brazilians as well.  
 
The MCMI-III is composed of 175 statements and individuals completing the test must indicate whether 
they think these statements are true or false for them. Examples of these statements are: “I think I am a very 
sociable and outgoing person” and “I often allow others to make important decisions for me.” If I decide to 
participate in this study, I will be answering three small questionnaires (10 - 11 questions each) in addition 
to the MCMI-III. The purpose of these questionnaires is to gather information about my age, gender, 
marital status, educational and occupational level, history of alcohol problems and drug abuse, history of 
substance abuse treatment. By matching my MCMI-III answers with the information gathered through the 
questionnaires, the researchers will be able to determine whether or not the MCMI-III was helpful in 
assessing my substance abuse behavior.  
 
The person administering the MCMI-III and questionnaires will strive to arrange the testing session to 
accommodate my schedule. Only one testing session will be required. This session is expected to last 
between 30 to 40 minutes. No follow-up interview will be needed 
 
II. Risks and Benefits 
 
I understand that there is no direct benefit to me for agreeing to be in this study. The researchers will not 
interpret the overall results of my test and will not be able to provide me with information about my scores.  
 
One possible risk to me is that I may initially feel uncomfortable taking the test because it will require 
answering items about my attitudes toward aspects of my life that I may consider private. However, I don’t 
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have to identify myself by name on the answer sheets and, therefore, my answers can not be traced back to 
me. If I have any concerns about my participation in this study, I can discuss them with the research 
associate in charge of data collection, Monica Schaly, whose phone number is listed above. 
 
III. Costs and Payments 
 
Participation in this study is voluntary and involves no costs to me. I understand that I will not receive 
payment for my participation. 
 
IV. Confidentiality 
 
All information obtained will be keep strictly confidential unless disclosure is required by Brazilian or 
United States law. I understand that I don’t need to identify myself by name on the test answer sheets. 
Instead, I will be asked to use a number to help the researchers match my answers on the primary test with 
my answers on other testing materials without knowing they belong to me. To further protect my identity, 
any publications from this study will be written without identifying information. I understand that the 
protection of my identity is regarded as an issue of the utmost importance by the researchers and that my 
confidentiality will be safeguarded. 
 
If I am a patient at the Pater-Aldeia Clinic, Santa Casa de Misericórdia Hospital, or Primeira Clinica 
Popular do Estado do Rio de Janeiro I authorize Monica Schaly to have access to my medical records at the 
Pater-Aldeia Clinic, Santa Casa de Misericórdia Hospital or Primeira Clinica Popular do Estado do Rio de 
Janeiro. The purpose of this authorization is to allow the researcher to get information about my diagnosis. 
I understand that I can revoke this authorization at any time by providing a signed written statement to 
Monica Schaly. Although I will not be able to participate in the study procedures if I decide not to give the 
authorization, my treatment at the Pater-Aldeia Clinic, Santa Casa de Misericórdia Hospital, or Primeira 
Clinica Popular do Estado do Rio de Janeiro will not be affected in any way by my refusal to authorize the 
researcher’s access to my records. If I allow this transfer of information from my medical file, the 
researchers will protect the confidentiality of this information as discussed in the Confidentiality section 
above.   
 
V. Right to Withdraw 
 
I understand that I may discontinue the testing at any time either during or after the study and have all my 
answers destroyed unless prohibited by state or federal law. If any significant new information relating to 
the study becomes available which may relate to my willingness to continue to participate, this information 
will be provided to me by the investigators. 
 
VI. Voluntary Consent 
 
I have read the preceding consent form, or it has been read to me, and I fully understand the 
contents of this document and voluntarily consent to participate. All of my questions concerning the 
research have been answered. I hereby agree to participate in this research study. If I have any 
questions in the future about this study they will be answered by Monica Schaly or any of the other 
researchers.  If I am a client at the Pater-Aldeia Clinic, Santa Casa de Misericórdia Hospital, or 
Primeira Clinica Popular do Estado do Rio de Janeiro I also voluntarily agree to the release of my 
medical diagnosis as described in this document. For questions relating to my rights as a participant 
of this study, I can contact the president of the Research Ethics Committee of the Núcleo de Estudos 
em Saúde Coletiva do Rio de Janeiro, Dr. Marisa Palácios, at (021) 2598-9278. A copy of this form 
has been given to me. This consent ends at the conclusion of this study. 
 
________________________________________________________________________ 
Participant’s Signature       Date 
 
________________________________________________________________________ 
Witness Signature       Date 
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APPENDIX D 
 
Informed Consent (Portuguese Version) 
Validade da escala de abuso de substâncias químicas da versão brasileira do MCMI-III 
 
Pesquisador principal:    
Cristina Magalhães 
Psicóloga e Mestre em Psicologia Clínica 
    251 NE 38th ST #309 
    Oakland Park, FL 33334 EUA 
    Telefone: (954) 568-1106 
    E-mail: magalhac@nova.edu 
 
Professores orientadores da pesquisa: 
    Alfred Sellers, Ph.D.
    3301 College Avenue 
    Fort Lauderdale, FL 33314 EUA 
    Telefone: (954) 262-5810 
    E-mail: sellers@nova.edu 
 
Colaborador: 
Mônica Schaly 
Psicóloga e Mestre em Orientação de Saúde Mental 
    Telefone: 011 55 (021) 3393-2687 
    E-Mail: billynile@yahoo.com.br 
 
    Linda Sobell, Ph.D. 
    3301 College Avenue 
    Fort Lauderdale, FL 33314 EUA 
    Telefone: (954) 262-5811 
    E-mail: sobelll@nova.edu 
 
Comitê de Ética da Universidade: 
    Número do projeto: CPS07060401X 
    Data de aprovação: 15/07/04 
   Agência patrocinadora: nenhuma 
   Telefone: (954) 262-5369 
 
    John Lewis, Ph.D. 
    3301 College Avenue 
    Fort Lauderdale, FL 33314 EUA 
    Telefone: (954) 262-5729 
    E-mail: lewis@nova.edu 
 
I. Descrição do estudo: 
 
Fui informado(a) de que a pesquisadora Cristina Magalhães está conduzindo um estudo científico com o 
objetivo de cumprir os requerimentos do seu curso de doutorado em Psicologia Clínica pela Nova 
Southeastern University. Também fui informado(a) de que este estudo tem por objetivo avaliar a validade 
da versão brasileira do Inventório Clínico e Multiaxial-III (MCMI-III) para o diagnóstico de problemas de 
abuso de substâncias químicas na população brasileira.  
 
O MCMI-III é um teste psicológico que foi desenvolvido com o objetivo de facilitar a identificação de 
vários distúrbios de personalidade e síndromes clínicas em pessoas com diferentes tipos de problemas, 
inclusive abuso de substâncias químicas. Este teste foi originalmente desenvolvido em inglês e é 
considerado válido para utilização com pessoas que vivem nos Estados Unidos. Os pesquisadores estão 
interessados em avaliar se este teste também pode ser útil no diagnóstico de problemas de abuso de 
substâncias químicas em brasileiros. 
 
O MCMI-III é composto de 175 frases (declarações), e as pessoas que participam deste teste devem indicar 
se pensam que essas frases se aplicam ou não a elas (se são verdadeiras ou falsas). Exemplos dessas frases 
são: “Eu me considero uma pessoa muito sociável e extrovertida” e “Eu costumo deixar que outros tomem 
decisões importantes por mim”. Se eu decidir participar deste estudo, estou ciente de que, além do MCMI-
III, vou responder a três pequenos questionários (10 a 11 questões). O objetivo destes questionários é 
coletar informações sobre a minha idade, sexo, estado civil, ocupação, educação, histórico de problemas 
com abuso de substâncias químicas e tratamentos. Comparando as minhas respostas no MCMI-III com as 
informações obtidas através destes questionários, os pesquisadores serão capazes de avaliar se o MCMI-III 
foi ou não útil para identificar o meu comportamento em termos de uso de substâncias químicas.  
 
A pessoa responsável por administrar o teste fará o possível para que a sessão de testagem seja realizada 
segundo a minha conveniência. Somente uma sessão de testagem será necessária, e esta deverá durar de 30 
a 40 minutos. Não será necessária nenhuma sessão para entrega de resultados. 
 
II. Riscos e benefícios 
 
Estou ciente de que não serei beneficiado(a) diretamente por participar deste estudo. Os pesquisadores não 
irão produzir uma interpretação geral das minhas respostas e, portanto, não poderão me fornecer 
informações sobre o meu resultado.  
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Se eu participar deste estudo, o único risco que posso correr é o de me sentir um pouco constrangido(a) por 
estar respondendo a perguntas sobre aspectos da minha vida que considero privados. Entretanto, sei que 
não precisarei me identificar pelo meu nome nas folhas de resposta e, portanto, que minhas respostas não 
poderão ser reconhecidas como pertencentes a mim. Se eu tiver qualquer pergunta referente à minha 
participação neste estudo, sei que posso contatar a pessoa responsável pela coleta de dados, Monica Schaly, 
cujo número telefônico está listado acima.  
 
III. Custos e gratificações 
 
Minha participação neste estudo é voluntária. Eu compreendo que não receberei nenhum incentivo 
financeiro pela minha participação. 
 
IV. Confidencialidade 
 
Todas as informações obtidas pelos pesquisadores serão consideradas de caráter confidencial, a menos que 
a divulgação das mesmas seja exigida pela legislação brasileira ou norte-americana. Eu compreendo que 
não preciso me identificar pelo meu nome nas folhas de resposta, mas sei que serei instruído(a) a usar um 
número de identificação para que os pesquisadores possam combinar minhas folhas de resposta sem saber 
que pertencem a mim. Para proteger minha identidade, qualquer publicação futura a respeito deste estudo 
será feita de modo a que nenhuma informação possa identificar qualquer um dos participantes. Eu 
compreendo que a proteção da minha identidade é considerada um assunto de grande importância para os 
pesquisadores e que minha confidencialidade será preservada.  
 
Caso eu seja um paciente na Clínica Pater-Aldeia, Santa Casa de Misericórdia do Rio de Janeiro, ou 1ª 
Clínica Popular do Estado do Rio de Janeiro, autorizo Mônica Schaly a ter acesso ao meu prontuário 
médico da clínica/hospital. O propósito desta autorização é conceder permissão aos pesquisadores para que 
possam obter informações sobre o meu diagnóstico. Eu compreendo que posso revogar essa autorização a 
qualquer momento, entregando um pedido por escrito à Mônica Schaly. Caso eu decida não autorizar o 
acesso dos pesquisadores ao meu prontuário médico, sei que não poderei participar da pesquisa, mas 
entendo que o meu tratamento na Clínica Pater-Aldeia, Santa Casa de Misericórdia do Rio de Janeiro, ou 1ª 
Clínica Popular do Estado do Rio de Janeiro, não será alterado ou prejudicado de forma alguma. Se eu 
permitir o acesso dos pesquisadores ao meu prontuário médico, eles protegerão a confidencialidade dessas 
informações conforme discutido no parágrafo acima.   
 
V. Direito de desistência 
 
Eu compreendo que tenho o direito de interromper minha testagem e pedir que todas as minhas respostas 
sejam destruídas (durante ou depois de o estudo ter sido concluído), exceto em situações em que tal 
procedimento seja proibido pela legislação estadual ou federal. Se alguma informação nova a respeito desse 
estudo se tornar disponível e puder ter alguma influência na minha decisão de participar, esta informação 
me será fornecida pelos pesquisadores.  
 
VI. Consentimento voluntário 
 
Atesto que li este consentimento de participação (ou me foi lido por outra pessoa), compreendo totalmente o conteúdo deste 
documento, e concordo em participar voluntariamente desta pesquisa. Todas as minhas dúvidas referentes a este estudo foram 
respondidas. Eu concordo em participar deste estudo. Se no futuro tiver perguntas a respeito deste estudo, sei que serão 
respondidas por Mônica Schaly ou qualquer um dos outros pesquisadores. Caso eu seja um paciente da Clínica Pater-Aldeia, 
Santa Casa de Misericórdia do Rio de Janeiro, ou 1ª Clínica Popular do Estado do Rio de Janeiro, também voluntariamente 
concordo com o acesso dos pesquisadores ao meu diagnóstico médico, conforme descrito neste documento. Para questões 
relacionadas aos seus direitos como paciente do estudo de pesquisa, contate a Presidente do Comitê de Ética em Pesquisa do 
Núcleo de Estudos em Saúde Coletiva do Rio de Janeiro, Dra. Marisa Palácios, tel: 2598 9278. Recebi uma cópia deste 
consentimento de participação. Este consentimento será válido somente até a conclusão deste estudo. 
 
________________________________________________________________________ 
Assinatura do(a) participante voluntário(a) da pesquisa   Data 
 
________________________________________________________________________ 
Assinatura da testemunha       Data 
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APPENDIX E 
 
The Alcohol Dependence Scale Composition and Item Weighing  
for the Original and Translated Versions of the MCMI-III (Millon, 1997). 
 
True Prototypal Items (weigh = 2) 
 
52 I have an alcohol problem that has made 
difficulties for me and my family. 
Eu tenho um problema com bebida alcoólica, 
que já gerou dificuldades para mim e minha 
família. 
77 I have a great deal of trouble trying to control 
an impulse to drink to excess. 
Eu tenho bastante dificuldade de controlar um 
impulso de beber em excesso. 
100 I guess I’m no different from my parents in 
becoming somewhat of an alcoholic. 
Eu acho que não sou diferente dos meus pais em 
me tornar um pouco alcoólatra. 
131 Drinking alcohol helps when I’m feeling 
down. 
Tomar bebida alcoólica ajuda quando me sinto 
deprimido. 
152 I have a drinking problem that I’ve tried 
unsuccessfully to end. 
Eu tenho um problema com bebida alcoólica 
que já tentei acabar, mas não fui bem sucedido. 
 
True Nonprototypal Items (weigh = 1) 
 
14 Sometimes I can be pretty rough and mean in 
my relations with my family. 
Ás vezes sou bastante rude e perverso com a 
minha família. 
41 I’ve done a number of stupid things on 
impulse that ended up causing me a great 
trouble. 
Já fiz várias coisas estúpidas sem pensar, que 
acabaram me causando grandes problemas. 
64 I don’t know why, but I sometimes say cruel 
things just to make others unhappy. 
Não sei porque, mas às vezes eu falo coisas 
cruéis só para fazer os outros infelizes. 
93 There are members of my family who say I’m 
selfish and think only of myself. 
Alguns membros da minha família dizem que 
sou egoísta e que só penso em mim mesmo. 
101 I guess I don’t take many of my family 
responsibilities as seriously as I should. 
Eu acho que não levo muitas das minhas 
responsabilidades familiares tão à sério quanto 
deveria. 
113 I’ve gotten into trouble with the law a couple 
of times. 
Eu me envolvi em problemas com a lei algumas 
vezes. 
122 I seem to make a mess of good opportunities 
that come my way. 
Parece que estrago as boas oportunidades que 
me surgem. 
139 I’m very good at making up excuses when I 
get into trouble. 
Eu sou muito bom em inventar desculpas 
quando me envolvo em encrencas. 
166 I act quickly much of the time and don’t think 
things through as I should. 
Na maioria das vezes eu ajo impulsivamente e 
sem pensar nas consequências como deveria. 
 
False Prototypal Item (weight = 2) 
 
23 Drinking alcohol has never caused me any 
real problems in my work. 
Bebida alcoólica nunca me causou grandes 
problemas no meu trabalho. 
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APPENDIX F 
 
The Drug Dependence Scale Composition and Item Weighing  
for the Original and Translated Versions of the MCMI-III (Millon, 1997) 
 
True Prototypal Items (weigh = 2) 
 
13 My drug habits have often gotten me into a 
good deal of trouble in the past. 
Meu uso de drogas já me causou muitos 
problemas no passado. 
39 Taking so-called illegal drugs may be unwise, 
but in the past I found I needed them. 
Fazer uso de drogas ilegais pode ser uma 
imprudência, mas no passado eu precisei delas. 
66 My habit of abusing drugs has caused me to 
miss work in the past. 
Meu hábito de abusar de drogas me fez perder 
dias de trabalho. 
91 My use of so-called illegal drugs has led to 
family arguments. 
Meu uso de drogas ilegais já causou discussões 
de família.  
118 There have been times when I couldn’t get 
through the day without some street drugs. 
Ja existiram épocas em que eu não conseguia 
passar o dia sem usar drogas. 
136 I know I’ve spent more money than I should 
buying illegal drugs. 
Eu sei que gastei mais dinheiro do que deveria 
comprando drogas. 
 
True Nonprototypal Items (weigh = 1) 
 
7 If my family puts pressure on me, I’m likely 
to feel angry and resist doing what they want. 
Quando a minha família me pressiona, eu 
costumo ficar zangado e procuro não fazer o 
que eles querem. 
21 I like to flirt with members of the opposite 
sex. 
Gosto de flertar (paquerar) com as pessoas do 
sexo oposto. 
38 I do what I want without worrying about its 
effect on others.  
Faço o que quero sem me preocupar como isso 
afeta os outros. 
41 I’ve done a number of stupid things on 
impulse that ended up causing me great 
trouble.  
Já fiz várias coisas estúpidas sem pensar, que 
acabaram me causando grandes problemas. 
53 Punishment has never stopped me from doing 
what I wanted. 
Nunca deixei de fazer o que eu queria por medo 
de ser castigado. 
101 I guess I don’t take many of my family 
responsibilities as seriously as I should. 
Eu acho que não levo muitas das minhas 
responsabilidades familiares tão à sério quanto 
deveria.  
113 I’ve gotten into trouble with the law a couple 
of times. 
Eu me envolvi em problemas com a lei algumas 
vezes. 
139 I’m very good at making up excuses when I 
get into trouble. 
Eu sou muito bom em inventar desculpas 
quando me envolvo em encrencas. 
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 APPENDIX G 
 
Diagnostic Questionnaire (English Version) 
 
 
Past Use of Alcohol Questions 
 
The following statements are about your alcohol use over the past 12 months. Please check YES for those statements 
that describe your drinking during the past 12 months, and check NO for those statements that are not true for you. 
                        
Yes     No 
1. In the past 12 months, I often used alcohol in larger amounts or over longer periods of time 
than I intended. 
F F
2. In the past 12 months, I often wanted to or tried to cut down or control my alcohol use. F F
3. In the past 12 months, I spent a lot of time either (a) using alcohol, (b) in activities trying to 
obtain alcohol, or (c) recovering from the effects of my drinking. 
F F
4. In the past 12 months, I gave up or reduced my involvement in important social, occupational, 
or recreational activities because of my alcohol use. 
F F
5. In the past 12 months, I continued to use alcohol despite knowing that it likely caused or made 
worse psychological or physical problems I had (e.g., continued drinking knowing it was 
making my ulcer or depression worse). 
F F
6. In the past 12 months, I found I needed greater amounts of alcohol than I use to in order to feel 
intoxicated or to get a desired effect, OR I got much less of an effect by using the same amount 
of alcohol as in the past. 
F F
7. In the past 12 months, I experienced withdrawal symptoms when I tried to cut down or stop my 
drinking OR I drank alcohol to relieve or avoid withdrawal symptoms. IF YES, PLEASE 
DESCRIBE YOUR WITHDRAWAL SYMPTOMS: 
_________________________________________________ 
 
F F
8. In the past 12 months, my continued alcohol use resulted in my not fulfilling major obligations 
at work, school, or home (e.g., repeated absences or poor performances at work or school; 
neglecting my children or home). 
 
F F
9. In the past 12 months, I repeatedly used alcohol in situations that were physically hazardous 
(e.g., driving a car or operating machinery). 
 
F F
10. In the past 12 months, my drinking has resulted in my having recurrent substance-related legal 
problems. 
 
F F
11. In the past 12 months, I continued to use alcohol despite having persistent or recurrent social or 
interpersonal problems caused or made worse by the effects of my drinking (e.g., arguments 
with friends or family about my drinking or physical fights). 
 
F F
If 3 or more YES responses are given for Items 1 through 7, then the criteria for 
dependence (303.90) have been satisfied. 
F F
 O
FF
IC
E
 U
SE
 
O
N
L
Y
 
If 1 or more YES response(s) are given for Items 8 through 11, then the criteria for abuse 
(305.00) have been satisfied.  
 
F F
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Past Use of Drug Questions 
 
 
The following questions are about your use of the drug __________________over the past 12 months. Please check 
YES for those statements that describe your use of ___________________ over the past 12 months, and check NO for 
those statements that are not true for you. 
 
 
                        Yes     No 
1. In the past 12 months, I often used (drug listed above) in larger amounts or over longer 
periods of time than I intended. 
F F
2. In the past 12 months, I often wanted to or tried to cut down or control my use of (drug listed 
above). 
F F
3. In the past 12 months, I spent a lot of time either (a) using (drug listed above), (b) in activities 
trying to obtain (drug listed above), or (c) recovering from the effects of my use of (drug 
listed above). 
F F
4. In the past 12 months, I gave up or reduced my involvement in important social, occupational, 
or recreational activities because of my use of (drug listed above). 
F F
5. In the past 12 months, I continued to use (drug listed above) despite knowing that it likely 
caused or made worse psychological or physical problems I had (e.g., continued drug knowing 
it was making my hepatitis or depression worse. 
F F
6. In the past 12 months, I found that I needed greater amounts of (drug listed above) than I use 
to in order to feel intoxicated or to get a desired effect OR that I got much less effect by using 
the same amount of (the drug listed above) as in the past. 
F F
7. In the past 12 months, I experienced withdrawal symptoms when I tried to cut down or stop my 
use of use of (drug listed above) OR I took (drug listed above) to relieve or avoid withdrawal 
symptoms. IF YES, PLEASE DESCRIBE YOUR WITHDRAWAL SYMPTOMS: 
_________________________________________________
_________________________________________________
_________________________________________________
___ 
 
F F
8. In the past 12 months, my continued use of (drug listed above) resulted in my not fulfilling 
major obligations at work, school, or home (e.g., repeated absences or poor performances at 
work or school; neglecting my children or home). 
 
F F
9. In the past 12 months, I repeatedly used (drug listed above) in situations that were physically 
hazardous (e.g., driving a car or operating machinery). 
 
F F
10. In the past 12 months, my use of (drug listed above) has resulted in my having recurrent 
substance-related legal problems. 
 
F F
11. In the past 12 months, I continued to use (drug listed above) despite having persistent or 
recurrent social or interpersonal problems caused or made worse by the effects of my use of 
(e.g., arguments with friends or family about my drug use or physical fights). 
 
F F
If 3 or more YES responses are given for Items 1 through 7, then the criteria for dependence 
have been satisfied.  
F F
 O
FF
IC
E
 U
SE
 
O
N
L
Y
 
If 1 or more YES response(s) is given for Items 8 through 11, then the criteria for abuse 
have been satisfied. 
F F
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APPENDIX H 
Diagnostic Questionnaire (Portuguese Version) 
 
 
Perguntas Relacionadas ao Consumo de Bebidas Alcoólicas 
 
As perguntas a seguir referem-se ao seu consumo de bebidas alcoólicas nos últimos 12 meses. Favor responder SIM 
para os itens que descrevem corretamente o seu consumo de álcool nos últimos 12 meses e NÃO para os itens que não 
se aplicam a você.  
 SIM    NÃO 
1. Nos últimos 12 meses, tomei muitas vezes bebidas alcoólicas em quantidades maiores do que 
tinha planejado ou durante períodos mais longos do que tinha planejado. F F
2. Nos últimos 12 meses, quis muitas vezes parar de beber ou tentei diminuir ou controlar o meu 
consumo de bebidas alcoólicas.  F F
3. Nos últimos 12 meses, perdi muito tempo usando bebidas alcoólicas, em atividades que tinham 
o propósito de obter bebidas alcoólicas, ou me recuperando dos efeitos do uso de bebidas 
alcoólicas.  
F F
4. Nos últimos 12 meses, por causa da bebida, parei ou reduzi o meu envolvimento em atividades 
importantes de caráter social, de trabalho, ou lazer. 
F F
5. Nos últimos 12 meses, continuei consumindo bebidas alcoólicas apesar de saber que o álcool 
estava causando ou agravando alguns dos meus problemas físicos ou psicológicos (por 
exemplo, continuei a beber mesmo sabendo que a bebida estava piorando a minha úlcera ou 
depressão).  
F F
6. Nos últimos 12 meses, precisei aumentar a quantidade de bebidas alcoólicas que consumia para 
poder me sentir intoxicado ou para conseguir o efeito desejado. OU, passei a sentir um efeito 
bem menor do que eu costumava sentir no passado bebendo a mesma quantidade de álcool.  
F F
7.    Nos últimos 12 meses, senti sintomas de abstinência quando tentei diminuir ou parar de 
beber OU consumi bebidas alcoólicas para aliviar ou evitar sintomas de abstinência. SE A 
SUA RESPOSTA FOR SIM, FAVOR DESCREVER ABAIXO SEUS SINTOMAS DE 
ABSTINÊNCIA: 
_______________________________________________ 
F F
8.   Nos últimos 12 meses, não consegui desempenhar bem minhas funções no trabalho, escola ou 
casa por causa do meu uso contínuo de álcool (por exemplo, perdi muitos dias de trabalho ou 
escola; ou deixei de dar atenção aos meus filhos ou negligenciei a minha casa). 
F F
9.  Nos últimos 12 meses, muitas vezes eu bebi em situações que eram perigosas e poderiam me 
causar danos físicos (por exemplo, dirigindo um carro ou manipulando máquinas). F F
10. Nos últimos 12 meses, tive vários problemas com a lei decorrentes do meu consumo de álcool.  F F
11.  Nos últimos 12 meses, continuei a beber embora tenha enfrentado problemas de relacionamento 
ou problemas sociais constantes ou recorrentes, os quais foram causados ou agravados pelos 
efeitos da bebida (por exemplo, discussões com amigos ou familiares sobre o meu consumo de 
álcool ou brigas). 
F F
If 3 or more YES responses are given for Items 1 through 7, then the criteria for dependence 
have been satisfied.  
F F
O
FF
IC
E 
U
SE
 
O
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L
Y
 
If 1 or more YES response(s) is given for Items 8 through 11, then the criteria for abuse 
have been satisfied. 
F F
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Perguntas Relacionadas ao Uso de Drogas 
 
As perguntas a seguir referem-se ao seu uso da droga ________________________ nos últimos 12 meses. Favor 
responder SIM para os itens que descrevem corretamente o seu uso de ________________________ nos últimos 12 
meses e NÃO para os itens que não se aplicam a você.  
 
    SIM     NÃO 
1. Nos últimos 12 meses, usei muitas vezes a droga acima citada em quantidades maiores do que 
tinha planejado ou durante períodos mais longos do que tinha planejado. F F
2. Nos últimos 12 meses, quis muitas vezes parar de usar ou tentei diminuir ou controlar o meu 
uso da droga acima citada.  F F
3. Nos últimos 12 meses, perdi muito tempo usando a droga acima citada, em atividades que 
tinham o propósito de obter a droga, ou me recuperando dos efeitos do uso da droga.  
F F
4. Nos últimos 12 meses, por causa da droga acima citada, parei ou reduzi o meu envolvimento 
em atividades importantes de caráter social, de trabalho, ou lazer. 
F F
5. Nos últimos 12 meses, continuei o uso da droga acima citada apesar de saber que estava 
causando ou agravando alguns dos meus problemas físicos ou psicológicos (por exemplo, 
continuei a usar a droga mesmo sabendo que estava piorando a minha hepatite ou depressão).  
F F
6. Nos últimos 12 meses, precisei aumentar a quantidade da droga acima citada que usava para 
poder me sentir intoxicado ou para conseguir o efeito desejado. OU, passei a sentir um efeito 
bem menor do que eu costumava sentir no passado usando a mesma quantidade da droga.  
F F
7. Nos últimos 12 meses, senti sintomas de abstinência quando tentei diminuir ou parar de 
usar a droga acima citada OU usei a droga para aliviar ou evitar sintomas de abstinência. 
SE A SUA RESPOSTA FOR SIM, FAVOR DESCREVER ABAIXO SEUS SINTOMAS 
DE ABSTINÊNCIA: 
_______________________________________________
_______________________________________________ 
F F
8. Nos últimos 12 meses, não consegui desempenhar bem minhas funções no trabalho, escola ou 
casa por causa do meu uso contínuo da droga acima citada (por exemplo, perdi muitos dias de 
trabalho ou escola; ou deixei de dar atenção aos meus filhos ou negligenciei a minha casa). 
F F
9. Nos últimos 12 meses, muitas vezes eu usei a droga acima citada em situações que eram 
perigosas e poderiam me causar danos físicos (por exemplo, dirigindo um carro ou 
manipulando máquinas). 
F F
10. Nos últimos 12 meses, tive vários problemas com a lei decorrentes do meu uso da droga acima 
citada.  F F
11. Nos últimos 12 meses, continuei a usar a droga acima citada embora tenha enfrentado 
problemas de relacionamento ou problemas sociais constantes ou recorrentes, os quais foram 
causados ou agravados pelos efeitos da droga (por exemplo, discussões com amigos ou 
familiares sobre o meu uso da droga ou brigas). 
F F
If 3 or more YES responses are given for Items 1 through 7, then the criteria for dependence 
have been satisfied.  
F F
O
FF
IC
E 
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If 1 or more YES response(s) is given for Items 8 through 11, then the criteria for abuse 
have been satisfied. 
F F
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APPENDIX I 
 
English Version of the Alcohol Use Disorders Identification Testa 
 
1. How often do you have a drink containing 
alcohol? 
 
 
   (0) Never [Skip to Qs 9-10] 
   (1) Monthly or less 
   (2) 2 to 4 times a month 
   (3) 2 to 3 times a week 
   (4) 4 or more times a week 
  
6. How often during the last year have you needed a 
first drink in the morning to get yourself going 
after a heavy drinking session? 
 
   (0) Never 
   (1) Less than monthly 
   (2) Monthly 
   (3) Weekly 
   (4) Daily or almost daily 
               
2. How many drinks containing alcohol do you 
have on a typical day when you are drinking? 
 
   (0) 1 or 2 
   (1) 3 or 4 
   (2) 5 or 6 
   (3) 7, 8, or 9 
   (4) 10 or more 
 
7. How often during the last year have you had a 
feeling of guilt or remorse after drinking? 
 
   (0) Never 
   (1) Less than monthly 
   (2) Monthly 
   (3) Weekly 
   (4) Daily or almost daily 
 
3. How often do you have six or more drinks on 
one occasion? 
 
 
   (0) Never 
   (1) Less than monthly 
   (2) Monthly 
   (3) Weekly 
   (4) Daily or almost daily 
 
8. How often during the last year have you been 
unable to remember what happened the night 
before because you had been drinking? 
 
   (0) Never 
   (1) Less than monthly 
   (2) Monthly 
   (3) Weekly 
   (4) Daily or almost daily 
 
4. How often during the last year have you found 
that you were not able to stop drinking once 
you had started? 
 
   (0) Never 
   (1) Less than monthly 
   (2) Monthly 
   (3) Weekly 
   (4) Daily or almost daily 
 
9. Have you or someone else been injured as a 
result of your drinking? 
 
 
   (0) No 
   (2) Yes, but not in the last year 
   (4) Yes, during the last year 
 
5. How often during the last year have you failed 
to do what was normally expected from you 
because of drinking? 
 
   (0) Never 
   (1) Less than monthly 
   (2) Monthly 
   (3) Weekly 
   (4) Daily or almost daily 
 
10. Has a relative or friend or a doctor or another 
health worker been concerned about your 
drinking or suggested you cut down? 
 
   (0) No 
   (2) Yes, but not in the last year 
   (4) Yes, during the last year 
 
aBabor, Higgins-Biddle, Saunders, & Monteiro, 2001. 
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APPENDIX J 
 
Portuguese Version of the Alcohol Use Disorders Identification Test  
 
1.  Com que freqüência você consome bebidas 
alcoólicas? 
 
 
 
     (0) Nunca [vá para as questões 9-10] 
     (1) Mensalmente ou menos 
     (2) De 2 a 4 vezes por mês 
     (3) De 2 a 3 vezes por semana 
     (4) 4 ou mais vezes por semana        
 
6. Quantas vezes ao longo dos últimos 12 meses 
você precisou beber pela manhã para poder se 
sentir bem ao longo do dia após ter bebido 
bastante no dia anterior? 
 
     (0) Nunca 
     (1) Menos do que uma vez ao mês 
     (2) Mensalmente 
     (3) Semanalmente 
     (4) Todos ou quase todos os dias   
               
2. Quantas doses alcoólicas você consome 
tipicamente ao beber? 
 
 
     (0) 0 ou 1 
     (1) 2 ou 3 
     (2) 4 ou 5 
     (3) 6 ou 7 
     (4) 8 ou mais    
7. Quantas vezes ao longo dos últimos 12 meses 
você se sentiu culpado ou com remorso depois 
de ter bebido? 
 
     (0) Nunca 
     (1) Menos do que uma vez ao mês 
     (2) Mensalmente 
     (3) Semanalmente 
     (4) Todos ou quase todos os dias               
      
3.  Com que freqüência você consome cinco ou 
mais doses de uma vez? 
 
 
     (0) Nunca 
     (1) Menos do que uma vez ao mês 
     (2) Mensalmente 
     (3) Semanalmente 
     (4) Todos ou quase todas os dias      
 
8. Quantas vezes ao longo dos últimos 12 meses 
você foi incapaz de lembrar o que aconteceu 
devido à bebida? 
 
     (0) Nunca 
     (1) Menos do que uma vez ao mês 
     (2) Mensalmente 
     (3) Semanalmente 
     (4) Todos ou quase todos os dias       
4.  Quantas vezes ao longo dos últimos 12 meses 
você achou que não conseguiria parar de 
beber uma vez tendo começado? 
 
     (0) Nunca 
     (1) Menos do que uma vez ao mês 
     (2) Mensalmente 
     (3) Semanalmente 
     (4) Todos ou quase todos os dias      
 
9. Você já causou ferimentos ou prejuízos a você 
mesmo ou a outra pessoa após ter bebido? 
 
 
     (0) Não 
     (2) Sim, mas não nos últimos 12 meses 
     (4) Sim, nos últimos 12 meses   
 
5.   Quantas vezes ao longo dos últimos 12 
meses você, por causa do álcool, não 
conseguiu fazer o que era esperado de você?
 
     (0) Nunca 
     (1) Menos do que uma vez ao mês 
     (2) Mensalmente 
     (3) Semanalmente 
     (4) Todos ou quase todos os dias           
 
10. Algum parente, amigo ou médico já se 
preocupou com o fato de você beber ou sugeriu 
que você parasse? 
 
     (0) Não 
     (2) Sim, mas não nos últimos 12 meses 
     (4) Sim, nos últimos 12 meses   
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APPENDIX K 
 
Demographic Questionnaire 
 
No de Identificação:  
Identification Number       
Idade: 
Age 
Local de Coleta de Dados: 
Data Collection Site 
  (1) Santa Casa         (3) Igreja Betânia (5) Clinica Popular 
(2) Pater-Aldeia      (4) Igreja Congregacional 
Sexo:       
Gender             
(1) masculino            (2) feminino 
       male                             female                           
 
Estado Civil: 
Marital Status  
(1) solteiro/solteira 
       single 
(2) casado/casada  
      married 
(3) viúvo/viúva 
       widowed        
(4) separado ou divorciado 
     separated – divorced 
                                                 
   
Ocupação: 
Type of Work 
 (1) escritório 
      office                   
 (2) fábrica   
       factory               
 (3) profissional liberal 
      professional                           
 (4) desempregado     
      unemployed                       
 (5) outro _____________ 
       other 
Escolaridade: 
Educational Level 
  Primário:               (1) incompleto     (2) completo 
   elementary school          incomplete               complete 
  Ginásio:                (3) incompleto     (4) completo 
   middle school                incomplete               complete 
  2º grau:                 (5) incompleto     (6) completo 
   high school                    incomplete                complete 
  Universitário:        (7) incompleto      (8) completo 
   college                            incomplete                complete 
Pós-Universitário   (9) incompleto    (10) completo 
   graduate                          incomplete                complete 
                      
Principal Razão para o Tratamento: 
Primary Reason for Treatment 
   (1) problemas com uso de álcool            (2) problemas com uso de drogas           (3) problemas com uso de álcool e drogas 
       alcohol problems                                            drug problems                                                alcohol and drug problems 
Tratamentos Anteriores: 
Treatment History 
A. Quantas vezes você já recebeu tratamento para dependência ou abuso de alcool?  
         How many times in the past you received treatment for alcohol abuse/dependence? 
             (1) nenhuma vez            (2) 1 - 2 vezes          (3) 3 – 4 vezes         (4) 5 ou mais vezes 
                          never                                  1 – 2 times                   3 – 4 times                   5 or more times 
B. Quantas vezes você já recebeu tratamento para dependência ou abuso de drogas? 
        How many times in the past you received treatment for drug abuse/dependence? 
            nenhuma vez           (2) 1 - 2 vezes          (3) 3 – 4 vezes         (4) 5 ou mais vezes (1) 
                never                                  1 – 2 times                   3 – 4 times                   5 or more times 
História de Uso: 
History of Substance Use 
        A.       Com que idade você começou a tomar bebidas alcoólicas? ____________  
                   At what age did you start drinking alcohol? 
B.     Com que idade você fez uso de drogas pela primeira vez? _____________ 
         At what age did you use illegal drugs for the first time? 
Religião: 
Religion 
(1) Nenhuma 
      none 
(2) Protestante 
      Protestant 
(3) Católica 
      Catholic 
(4) Espírita 
      Spiritism 
(5) Afro-Brasileira 
      Afro-Brazilian 
(6) Outra  
        other 
_________________
_________________ 
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APPENDIX L 
 
Instructions for Data Collection 
 
 
 
INTRODUCTION 
 
 
This document provides instructions regarding the recruitment of participants and the 
administration of the assessment instruments for the study titled “the Brazilian-
Portuguese MCMI-III: Diagnostic Validity of the Substance Dependence Scales.” It is 
important that any one involved in the data collection phase of this project, read, 
understand, and abide by all procedures described in this document. The reliability of the 
results obtained at the end of this study directly depends on how well and uniform the 
data will be produced. In case this manual does not answer all your questions regarding 
the recruitment of the participants and the administration of the assessment procedures, 
please contact the principal investigator, Cristina Magalhaes, either by e-mail 
(magalhac@nova.edu) or by phone (954-568-1106 or 954-937-0240).   
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I. Purpose of the Study 
 
 
This study seeks to evaluate the validity of the Brazilian-Portuguese version of the Millon 
Clinical Multiaxial Inventory-III (MCMI-III) for assessing substance abuse problems in 
the Brazilian population. The MCMI-III is a psychological test that was designed to 
measure personality traits and clinical syndromes in individuals with different types of 
problems, including substance abuse. This test was originally developed in the English 
language and has been considered valid for use with people who live in the United States. 
The researchers are interested in evaluating whether it can be useful for assessing 
substance abuse problems among Brazilians as well.  
 
The MCMI-III is composed of 175 statements and individuals completing the test must 
indicate whether they think these statements are true or false for them. Examples of these 
statements are: “I think I am a very sociable and outgoing person” and “I often allow 
others to make important decisions for me.” If they decide to participate in this study, 
they will be answering three small questionnaires (10 - 11 questions each) in addition to 
the MCMI-III. The purpose of these questionnaires is to gather information about their 
age, gender, marital status, educational and occupational level, history of alcohol 
problems and drug abuse, history of substance abuse treatment. By matching the 
participants’ MCMI-III answers with the information gathered through the 
questionnaires, the researchers will be able to determine whether or not the MCMI-III 
was helpful in assessing their substance abuse behavior.  
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II. Assessment Measures  
 
 
A. Description 
 
1) MCMI-III. The MCMI-III is a psychological test that was designed to measure 
personality traits and clinical syndromes in individuals with different types of 
problem. It has a total of 27 subscales: (a) 3 for estimating the individual’s test-
taking attitude, (b) 14 for measuring different personality styles, and (c) 10 for 
assessing the presence of clinical syndromes, including anxiety, depression, 
psychotic disorders, posttraumatic stress, and substance abuse/dependence. 
 
The MCMI-III is composed of 175 statements and individuals completing the test 
must indicate whether they think these statements are true or false for them. 
Examples of these statements are: “I think I am a very sociable and outgoing 
person” and “I often allow others to make important decisions for me.”  Due to the 
fact that the Portuguese language has gender-specific words, the development of 
gender-specific forms was deemed appropriate for use in the present study 
(masculine and feminine forms). 
 
2) AUDIT. The AUDIT is a screening instrument specifically used for the 
detection of mild to severe drinking problems. This instrument is a questionnaire 
containing 10 items related to alcohol consumption patterns, in which respondents 
are asked to select their answers from specified categories.   
 
3) Diagnostic Questionnaire. This instrument is a symptom checklist for 
diagnosing substance abuse and dependence according to the DSM-IV-TR. This 
instrument contains 11 yes-no questions, each corresponding to a specific 
diagnostic criterion listed under the DSM-IV-TR diagnostic code. Separate forms 
for alcohol and drug abuse/dependence are available.   
 
4) Demographic Questionnaire. This questionnaire will gather general 
information about the subjects’ age, gender, educational level, history of alcohol 
problems and drug abuse, history of substance abuse treatment, and admitting 
ICD-10 diagnosis (for participants receiving treatment at the Pater-Aldeia Clinic 
or Santa Casa de Misericordia Hospital).  
 
All participants (clinical and non-clinical) will be administered all instruments and are 
expected to complete the assessment packet approximately within 30 to 40 minutes. They 
should be administered the assessment materials in counterbalanced order to control for 
possible order effects. Approximately half of the total sample should complete the 
assessment measures in the following order: demographic questionnaire, BP-MCMI-III, 
AUDIT, and diagnostic questionnaire (assessment packet with green face-sheet and odd 
identification number). The other half should complete the assessment measures in the 
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following order: demographic questionnaire, AUDIT, diagnostic questionnaire, and BP-
MCMI-III (assessment packet with pink face-sheet and even identification number).  
 
B. Self-Report Measures 
 
All assessment instruments used in this study rely on respondent self-report. They were 
developed for use with adults (18 years-old and above) who know how to read and write.  
Preferably, subjects should have a minimum of 8th grade education. 
 
Self-report measures are most reliable when respondents have at least average 
intelligence, have no difficulty understanding the items, know themselves well enough to 
answer the questions accurately, and are willing to share what they know openly and 
nondefensively (Choca and Van Denburg, 1997). If during administration the examiner 
has reason to suspect that a particular subject is answering the questions in a way that 
would render the results unreliable, the answer sheets produced by this subject should be 
marked with a question mark sign (?) at the top left corner, for later identification of 
potentially unreliable protocols. The examiner should also write a brief explanation of 
why he/she believes the protocol may be invalid. 
 
Some respondents may find the MCMI-III questions strange or feel uncomfortable 
answering them. They may become self-conscious, thinking that the examiner may 
consider them “crazy” if they were asked to participate or that the test does not apply to 
them. In those situations the examiner should explain to the respondent that the test 
assesses many different types of personality and emotional difficulties people have and 
that it would be unlikely that respondents would identify themselves with all items. The 
examiner should then encourage the respondents to continue completing the assessment 
measures, reminding them of the confidentiality nature of their answers and the important 
contribution they are making to the study. 
 
The self-report measures are not difficult to answer but require that respondents be able 
to think clearly about their typical behaviors and their subjective experience. If 
respondents are feeling rushed or for any reason unable to concentrate while answering 
the test, their answers may be unreliable. To reduce the possibility of this happening, the 
assessment materials should be administered in a quiet, private, and well-lit room. Group 
administrations (more than one person answering the assessment materials at the same 
time and in the same room) are allowed and considered private if the respondents are 
answering the questions on their own, with no one looking over their shoulders or giving 
them opinions about how they should answer a particular question. Even if respondents 
say that they have nothing to hide from their partners, family members, or friends, the 
examiner must insist that the assessment materials be completed without anyone’s help or 
interference. The examiner should then tell the respondents that, after they complete the 
assessment materials, they are free to share the experience with anyone they chose to do 
so.  
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III. Data Collection Sites 
 
 
A.  Clinical Sample 
 
Clinical subjects will be recruited through two substance abuse treatment facilities in 
Brazil – the Pater-Aldeia Clinic and the Primeira Clínica Popular do Estado do Rio de 
Janeiro. Contact with the program directors of these institutions was made by the primary 
investigator, Cristina Magalhaes, and a written authorization for data collection was 
obtained. Contact information for the substance abuse treatment facilities involved in this 
study: 
 
Renato Mussi 
Clinica Pater-Aldeia 
E-mail: rmussi@nitnet.com.br  
 
Elen Fontes 
Primeira Clínica Popular do Estado do Rio de Janeiro 
E-mail: elenfontes@hotmail.com 
 
B.  Non-Clinical Sample 
 
Non-clinical subjects will be recruited through two churches in Brazil – the Igreja 
Evangélica Congregacional and the Igreja Presbiteriana Betânia in Rio de Janeiro. 
Contact with the leaders in charge of these congregations was made by the primary 
investigator, Cristina Magalhaes, and a written authorization for data collection was 
obtained. Contact information for the churches involved in this study: 
 
Rev. Marcos Moura 
Igreja Evangélica Congregacional 
E-mail: mamoura@minasgas.com.br 
 
Rev. Reginaldo Launé 
Igreja Presbiteriana Betânia 
E-mail: revregi@hotmail.com  
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IV. Selection of Participants 
 
 
A.  Clinical Sample 
 
Clinical participants should be selected based on the following criteria: (1) subject’s 
willingness to participate; (2) being above eighteen years of age; and (3) being in 
inpatient or outpatient treatment for alcohol/drug abuse or dependence. The clinical 
sample should include a minimum of 50 subjects with a diagnosis of alcohol abuse or 
dependence and 50 subjects with a diagnosis of drug abuse or dependence.  
 
B.  Non-Clinical Sample 
 
Non-clinical participants should be selected based on the following criteria: (1) subject’s 
willingness to participate; (2) being above eighteen years of age; and (3) having no 
history of substance abuse treatment. The non-clinical sample should include a minimum 
of 50 subjects. 
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IV.  Examiners 
 
 
The examiners are:  
 
1. Monica Schaly 
2. Vanda Guimarães 
3. Elaine Guimarães 
4. Vanete Ferreira 
5. Rachel Ferreira 
 
Monica Schaly is the research associate in charge of data collection in Brazil. She has a 
Masters degree in mental health counseling from Florida Atlantic University and is a 
licensed mental health counselor by the Florida Department of Health, with over 10 years 
of clinical experience. She was provided with research protocol and was fully trained by 
the primary investigator, Cristina Magalhaes, on all procedures for data collection.  
 
In addition to administering the assessment materials to the participants, Ms. Schaly is 
responsible for overseeing the implementation of the data collection procedures, 
supervising the research assistants, and ensuring consistency of instrument administration 
across examiners. The research assistants – Vanda Guimarães, Elaine Guimarães, Vanete 
Ferreira and Rachel Ferreira – were also directly trained by the principal investigator and 
will assist Ms. Schaly in all aspects of data collection. 
 
The primary investigator and the examiners will hold a phone meeting once weekly to go 
over any problems they may encounter during the previous week and decide on 
procedure modifications if necessary.  
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V.  The Role of the Examiner 
 
 
A. Recruitment: The examiner is responsible for explaining the purpose of the study 
to potential participants and to obtain their voluntary consent in collaborating with 
the project. The examiner is also responsible for explaining all procedures 
involved, including the risks and benefits associated with their participation, and 
their right to withdraw from the study at any time. The examiner should assure 
potential participants that their answers will be kept confidential and those who 
agree to participate will be asked to sign an Informed Consent Form. Before 
asking participants to sign, they should be given time to read the Informed 
Consent Form (or it should be read to them).  
 
B. Scheduling: Participants can complete the assessment materials immediately after 
they agree to participate in the study (after recruitment) or schedule an 
appointment to meet with the examiner at a later time or date - whichever will be 
more convenient for the participant and less disruptive of the site’s regular 
routine. The examiner is then responsible for discussing scheduling options with 
the participant and arriving at a decision of when it would be the best time to 
administer the assessment measures, based on the examiner’s availability and 
room availability. 
 
C. Administration: The examiner is responsible for providing the participants with 
an appropriate testing environment and the materials required for the completion 
of the test, which include 2 sharpened black-lead pencils, an eraser, and all testing 
forms contained in the assessment packet. For the purposes of this study, an 
appropriate testing environment is defined as a quiet, private, and well-lit room, 
with a table and a chair, or a chair with an attached writing surface, where the 
respondent can comfortably complete the testing materials. The examiner is also 
responsible for administering the different assessment instruments in the 
appropriate order (counterbalanced*). The examiner should instruct the 
participants on how to appropriately answer each instrument, by answering the 
first 1 or 2 items of each measure with them to ensure that the instructions have 
been understood. The examiner should let the participants know that he/she is 
available to answer any questions during the assessment procedure and encourage 
them to answer all items. In addition, the examiner is responsible for observing 
the participants during the test administration and noting any behavior that may 
indicate that they are completing the assessment packet in an unreliable manner. 
If during administration of the instruments the examiner has reason to suspect that 
a particular subject is answering the questions in a way that would render the 
results unreliable, the answer sheets produced by this subject should be marked 
with a question mark sign (?) at the top left corner, for later identification of 
potentially unreliable protocols. The examiner should also write a brief 
explanation of why he/she believes the protocol may be invalid. Before the full 
administration is complete, the examiner should obtain the ICD-10 diagnosis from 
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the participants’ medical file (for those participants that are receiving treatment 
for substance abuse) and ask them to record it on the Demographic Questionnaire. 
 
D. Post-Administration: After the participants complete all instruments the 
examiner should ask them to go over their own completed forms to see if they 
missed answering any items. One issue that may come up during the 
administration of the MCMI-III is the participants’ difficulty in deciding whether 
an item is true or false for them. Some may object to statements with the words 
always or never in them; and others may agree with parts of a statement while 
disagreeing with the rest. In such cases, the examiner should agree with the 
participant but encourage him or her to decide whether the statement is mostly 
true or false. The examiner should maintain the position that it is important that 
all items be answered, but if for any reason a participant refuses to answer an 
item, the examiner should say to the participant “it is OK not to answer this item 
if you don’t want to,” thank the person for participating in the study, and write the 
word “refused” next to the unanswered item. The examiner should make sure all 
forms completed by the same participant contain the same identification number 
and are stapled together to facilitate data entry. Signed Informed Consent Forms 
should be kept separate from completed assessment packets.  
 
 
